Ruxolitinib Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Ruxolitinib comprises 377 peer-reviewed publications across 15 journals, 31 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Primary Myelofibrosis, Graft vs Host Disease, COVID-19, and Dermatomyositis. Most recent publication: Efficacy and safety of ruxolitinib for graft-versus-host disease prophylaxis in patients with aplastic anemia undergoing PBSC-only allogeneic stem cell transplantation: a prospective phase II study., Exp Hematol Oncol, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease.
    Zeiser R, Polverelli N, Ram R, et al. · N Engl J Med · 2021
    PubMed: PMID 34260836 · NCT06756061 (FRONTJAK-001) · Graft vs Host Disease
  2. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.
    Wu Z, McGoogan JM · JAMA · 2020
    PubMed: PMID 32091533 · NCT04366232 (JAKINCOV) · COVID-19
  3. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial.
    Walker I, Panzarella T, Couban S, et al. · Lancet Haematol · 2020
    PubMed: PMID 31958417 · NCT04397367
  4. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
    Verstovsek S, Mesa RA, Gotlib J, et al. · N Engl J Med · 2012
    PubMed: PMID 22375971 · NCT00952289 · Primary Myelofibrosis
  5. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.
    Verstovsek S, Kantarjian H, Mesa RA, et al. · N Engl J Med · 2010
    PubMed: PMID 20843246 · NCT00509899 · Primary Myelofibrosis
  6. Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial.
    Rampal RK, Grosicki S, Chraniuk D, et al. · Nat Med · 2025
    PubMed: PMID 40065169 · NCT04603495 (MANIFEST-2) · Primary Myelofibrosis
  7. COVID-19: consider cytokine storm syndromes and immunosuppression.
    Mehta P, McAuley DF, Brown M, et al. · Lancet · 2020
    PubMed: PMID 32192578 · NCT04366232 (JAKINCOV) · COVID-19
  8. GSK-3β inhibitor, 9-ING-41, reduces cell viability and halts proliferation of B-cell lymphoma cell lines as a single agent and in combination with novel agents.
    Karmali R, Chukkapalli V, Gordon LI, et al. · Oncotarget · 2024
    PubMed: PMID 29383130 · NCT04218071 · Primary Myelofibrosis

Primary-outcome results across pivotal trials

Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.

TrialIndicationPrimary endpointArmValue
NCT00934544Primary MyelofibrosisPercentage of Participants With at Least 35% Reduction in Spleen Volume From Baseline at Week 48
Baseline, Week 48
Best Available Therapy (BAT)0 Percentage of Participants
Ruxolitinib28.5 Percentage of Participants
NCT00952289Primary MyelofibrosisNumber of Participants Achieving ≥ 35% Reduction in Spleen Volume From Baseline to Week 24
Baseline and Week 24
Placebo1 participants
Ruxolitinib65 participants
NCT01243944Polycythemia VeraThe Percentage of Participants Achieving a Primary Response at Week 32
32 Weeks
Best Available Therapy0.9 percentage of participants
Ruxolitinib22.7 percentage of participants
NCT01632904Polycythemia VeraPercentage of Subjects Achieving a ≥ 50% Improvement From Baseline in Total Symptom Score-Cytokine (TSS-C) at Week 16, as Measured by the Modified Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Diary
From Baseline to Week 16
Hydroxyurea29.6 Percentage of participants
Ruxolitinib43.4 Percentage of participants
NCT01969838
Simplify 1
Primary MyelofibrosisSplenic Response Rate at Week 24
Week 24
Momelotinib (MMB)57 Participants
Momelotinib (MMB)158 Participants
Ruxolitinib (RUX)153 Participants
Ruxolitinib (RUX)64 Participants
NCT02038036
RESPONSE-2
Myeloproliferative DisordersNumber of Participants Achieving Hematocrit (Hct) Control at Week 28
Week 28
Best Available Therapy (BAT)14 Participants
Ruxolitinib46 Participants
NCT02087059Primary MyelofibrosisNumber of Participants With Adverse Events as a Measure of Safety and Tolerability
24 weeks
Ruxolitinib33 Participants
Ruxolitinib46 Participants
Ruxolitinib38 Participants
Ruxolitinib5 Participants
Ruxolitinib33 Participants
Ruxolitinib36 Participants
Ruxolitinib5 Participants
Ruxolitinib50 Participants
Ruxolitinib12 Participants
NCT02117479Pancreatic NeoplasmsOverall Survival (OS)
Randomization until death due to any cause; up to the data cutoff 11FEB2016.
Placebo Plus Capecitabine124 Participants
Placebo Plus Capecitabine36 Participants
Ruxolitinib Plus Capecitabine113 Participants
Ruxolitinib Plus Capecitabine48 Participants
NCT02119663Pancreatic NeoplasmsOverall Survival (OS)
Randomization until death due to any cause up to 6-months or to the data cutoff 11FEB2016.
Placebo Plus Capecitabine23 Participants
Placebo Plus Capecitabine20 Participants
Ruxolitinib Plus Capecitabine29 Participants
Ruxolitinib Plus Capecitabine14 Participants
NCT02292446Myeloproliferative DisordersNumber of Participants With Adverse Events - All Grades
Baseline up to approximately 26 months
All Patients143 Participants
All Patients26 Participants
NCT02913261
REACH2
Graft vs Host DiseaseOverall Response Rate (ORR) at Day 28
Day 28
Best Available Therapy (BAT)39.4 Percentage of participants
Ruxolitinib (RUX)62.3 Percentage of participants
NCT03112603Graft vs Host DiseaseEfficacy of Ruxolitinib Versus Investigator's Choice Best Available Therapy (BAT) in Participants With Moderate or Severe Steroid Refractory Chronic Graft Versus Host Disease (SR-cGvHD) Assessed by Overall Response Rate (ORR) at the Cycle 7 Day 1 Visit
Cycle 7 Day 1 (each cycle was comprised of 4 weeks)
Best Available Therapy25.6 percentage of participants
Ruxolitinib49.7 percentage of participants
NCT03745638Dermatitis, AtopicPercentage of Participants Who Achieved Investigator's Global Assessment - Treatment Success (IGA-TS) at Week 8
Baseline to Week 8
VC Period: Ruxolitinib 0.75% Cream BID50.0 percentage of participants
VC Period: Ruxolitinib 1.5% Cream BID53.8 percentage of participants
VC Period: Vehicle Cream BID15.1 percentage of participants
NCT03745651Dermatitis, AtopicVC Period: Percentage of Participants Who Achieved Investigator's Global Assessment - Treatment Success (IGA-TS) at Week 8
Baseline to Week 8
VC Period: Ruxolitinib 0.75% Cream BID39.0 percentage of participants
VC Period: Ruxolitinib 1.5% Cream BID51.3 percentage of participants
VC Period: Vehicle Cream BID7.6 percentage of participants
NCT04052425VitiligoPercentage of Participants Achieving a ≥ 75% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI75) Score at Week 24
Baseline; Week 24
Double-Blind Period: Ruxolitinib Cream 1.5% BID29.8 percentage of participants
Double-Blind Period: Vehicle Cream BID7.4 percentage of participants
NCT04057573VitiligoPercentage of Participants Achieving a ≥ 75% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI75) Score at Week 24
Baseline; Week 24
Double-Blind Period: Ruxolitinib Cream 1.5% BID30.9 percentage of participants
Double-Blind Period: Vehicle Cream BID11.4 percentage of participants
NCT04362137
RUXCOVID
COVID-19Proportion of Patients Who Die, Develop Respiratory Failure [Require Mechanical Ventilation] or Require Intensive Care Unit (ICU) Care
Day 1 - Day 29
Placebo17 Participants
Ruxolitinib 5 mg34 Participants
NCT04377620COVID-19Percentage of Participants Who Have Died Due to Any Cause
Study start to Day 29
Placebo + Standard of Care (SoC)70.2 Percentage
Ruxolitinib 5mg + Standard of Care (SoC)52.9 Percentage
Ruxolitininb 15mg + Standard of Care (SoC)50.6 Percentage
NCT04472598
TRANSFORM-1
Primary MyelofibrosisPercentage of Participants With ≥ 35% Reduction From Baseline in Spleen Volume at Week 24 (SVR35W24)
Baseline, Week 24
Navitoclax + Ruxolitinib63.20 percentage of participants
Placebo for Navitoclax + Ruxolitinib31.50 percentage of participants
NCT04530344VitiligoTime to Relapse (Defined as <F-VASI75)
from Week 52 (first visit of this Treatment Extension study) to Week 104 (end of treatment in this Treatment Extension study)
Cohort A: Ruxolitinib 1.5% Cream BIDNA days
Cohort A: Vehicle Cream BIDNA days
NCT04551053Primary MyelofibrosisPercentage of Participants Achieving ≥25% Reduction in Spleen Volume From Baseline to Week 24 as Measured by Magnetic Resonance Imaging (MRI) (or Computed Tomography [CT] Scan in Applicable Participants)
Baseline; Week 24
Parsaclisib Plus Ruxolitinib16.7 percentage of participants
Placebo Plus Ruxolitinib9.7 percentage of participants
NCT04551066Primary MyelofibrosisPercentage of Participants Achieving ≥35% Reduction in Spleen Volume From Baseline to Week 24 as Measured by Magnetic Resonance Imaging [MRI] (or Computed Tomography [CT] Scan in Applicable Participants)
Baseline; Week 24
Parsaclisib Plus Ruxolitinib52.8 percentage of participants
Placebo Plus Ruxolitinib46.7 percentage of participants
NCT04603495
MANIFEST-2
Primary MyelofibrosisNumber of Participants With Splenic Response by Central Radiology Reads at Week 24
Week 24
Pelabresib + Ruxolitinib (Experimental Arm)141 Participants
Placebo + Ruxolitinib (Control Arm)76 Participants
NCT04921969Dermatitis, AtopicVC Period: Percentage of Participants Who Achieved Investigator's Global Assessment - Treatment Success (IGA-TS) at Week 8
Baseline to Week 8
VC Period: Ruxolitinib 0.75% Cream BID36.6 percentage of participants
VC Period: Ruxolitinib 1.5% Cream BID56.5 percentage of participants
VC Period: Vehicle Cream BID10.8 percentage of participants
NCT04934670
2002
Lymphoma, FollicularComplete Response (CR)
Day 28
Ruxolitinib0 Participants
T-Guard2 Participants
NCT05456529Dermatitis, AtopicNumber of Participants With ≥Grade 3 TEAEs
up to 462 days
Ruxolitinib 1.5% Cream BID3 Participants
NCT05456529Dermatitis, AtopicNumber of Participants With Treatment-emergent Adverse Events (TEAEs)
up to 462 days
Ruxolitinib 1.5% Cream BID42 Participants
NCT05755438
TRuE-PN1
Skin DiseasesWI-NRS4 Response at Week 12
Baseline; Week 12
Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID44.6 percentage of participants
Vehicle Cream BID to Ruxolitinib 1.5% Cream BID20.6 percentage of participants
NCT05764161
TRuE-PN2
Skin DiseasesWI-NRS4 Response at Week 12
Baseline; Week 12
Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID40.0 percentage of participants
Vehicle Cream BID to Ruxolitinib 1.5% Cream BID36.2 percentage of participants
NCT06238817
TRuE-AD4
Dermatitis, AtopicPercentage of Participants Achieving a ≥75% Improvement in the Eczema Area and Severity Index Score (EASI75) at Week 8
Baseline; Week 8
Ruxolitinib 1.5% Cream70.0 percentage of participants
Vehicle Cream18.5 percentage of participants
NCT06238817
TRuE-AD4
Dermatitis, AtopicPercentage of Participants With Investigator's Global Assessment Treatment Success (IGA-TS) at Week 8
Baseline; Week 8
Ruxolitinib 1.5% Cream61.3 percentage of participants
Vehicle Cream13.6 percentage of participants

Publications by year

1970–2026: 377 publications.

1970
1
1973
1
1974
1
1975
2
1978
1
1989
1
1993
1
1995
1
1998
1
2000
1
2001
1
2002
2
2003
1
2004
2
2005
3
2006
4
2007
1
2008
8
2009
6
2010
9
2011
7
2012
13
2013
4
2014
14
2015
21
2016
11
2017
27
2018
19
2019
27
2020
37
2021
34
2022
30
2023
26
2024
21
2025
25
2026
13

Publications by indication

Primary Myelofibrosis (94)

  • Preliminary Safety and Efficacy of Navitoclax Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis From the Multicenter, Open-Label, Phase 2 Study (REFINE).
    Hematol Oncol · 2026 · PMID 41846295 · NCT03222609
  • Association Between Transfusion Status, Hemoglobin Levels, and Patient-Reported Outcomes in Myelofibrosis: A Post Hoc Clinical Trial Analysis.
    Cancer Med · 2026 · PMID 41958363 · NCT01969838
  • Phase 1b study of ABBV-744, a novel, selective BET inhibitor, as monotherapy for patients with myelofibrosis.
    Blood Adv · 2026 · PMID 41843794 · NCT04454658
  • Selinexor plus ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis: a multicenter, open-label, phase 1 study.
    Blood Adv · 2026 · PMID 41785311 · NCT04562389
  • Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial.
    Nat Med · 2025 · PMID 40065169 · NCT04603495

Graft vs Host Disease (48)

  • Clinical considerations for ruxolitinib in the treatment of steroid-refractory acute graft-versus-host disease (GVHD) and steroid-refractory or -dependent chronic GVHD: a plain language summary.
    Ther Adv Hematol · 2026 · PMID 42180389 · NCT03112603
  • A randomized, multicenter phase II trial to compare prophylaxis of graft versus host disease with tacrolimus and mycophenolate mofetil versus ruxolitinib after post-transplant cyclophosphamide.
    Transplant Cell Ther · 2026 · PMID 42066960 · NCT04669210
  • Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study.
    J Clin Oncol · 2025 · PMID 40561385 · NCT03112603
  • Ruxolitinib Versus Best Available Therapy in Patients With Steroid-Refractory Acute Graft-Versus-Host Disease: Final Analysis From the Randomized Phase III REACH2 Trial.
    J Clin Oncol · 2025 · PMID 41092247 · NCT02913261
  • Impact of concomitant azoles on ruxolitinib treatment in patients with GVHD: post hoc analyses of REACH2 and REACH3.
    Blood Adv · 2025 · PMID 40472328 · NCT02913261

COVID-19 (44)

  • Multiarm multistage randomised controlled trial of inflammatory signal inhibitors (MATIS) for patients hospitalised with COVID-19 pneumonia during the UK pandemic.
    BMJ Open · 2026 · PMID 41644167 · NCT04581954
  • Ruxolitinib for Emergency Treatment of COVID-19-Associated Cytokine Storm: Findings From an Expanded Access Study.
    Clin Respir J · 2025 · PMID 40197709 · NCT04355793
  • Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet Rheumatol · 2024 · PMID 35368384 · NCT04362137
  • Ruxolitinib Rapidly Reduces Acute Respiratory Distress Syndrome in COVID-19 Disease. Analysis of Data Collection From RESPIRE Protocol.
    Front Med (Lausanne) · 2024 · PMID 32850921 · NCT04361903
  • Challenges for Drug Repurposing in the COVID-19 Pandemic Era.
    Front Pharmacol · 2023 · PMID 33240091 · NCT04348695

Dermatomyositis (27)

  • JAK Inhibitors: Prospects in Connective Tissue Diseases.
    Clin Rev Allergy Immunol · 2021 · PMID 32222877 · NCT06857240
  • Study of Tofacitinib in Refractory Dermatomyositis: An Open-Label Pilot Study of Ten Patients.
    Arthritis Rheumatol · 2021 · PMID 33258553 · NCT06857240
  • Effects of ruxolitinib cream on pruritus and quality of life in atopic dermatitis: Results from a phase 2, randomized, dose-ranging, vehicle- and active-controlled study.
    J Am Acad Dermatol · 2021 · PMID 32057960 · NCT06857240
  • Factors Associated With Clinical Remission of Skin Disease in Dermatomyositis.
    JAMA Dermatol · 2019 · PMID 29114741 · NCT06857240
  • JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis.
    Brain · 2019 · PMID 29741608 · NCT06857240

Dermatitis, Atopic (20)

  • Safety and Tolerability of Ruxolitinib Cream in Adolescents with Mild-to-Moderate Atopic Dermatitis: Results From a 1-Year, Phase III, Open-Label Study.
    Am J Clin Dermatol · 2026 · PMID 42201487 · NCT05456529
  • Ruxolitinib Cream As-Needed Monotherapy Demonstrates Sustained Disease and Symptom Control in Patients with Mild to Moderate Atopic Dermatitis: Pooled Analysis from Two Phase 3 Studies.
    Dermatol Ther (Heidelb) · 2026 · PMID 41678112 · NCT03745651
  • A Maximum-Use Trial of Ruxolitinib Cream in Children Aged 2-11 Years with Moderate to Severe Atopic Dermatitis.
    Am J Clin Dermatol · 2025 · PMID 39760983 · NCT05034822
  • Ruxolitinib Cream Monotherapy Improved Symptoms and Quality of Life in Adults and Adolescents with Mild-to-Moderate Atopic Dermatitis: Patient-Reported Outcomes from Two Phase III Studies.
    Am J Clin Dermatol · 2025 · PMID 39546129 · NCT03745638
  • Ruxolitinib cream monotherapy for facial and/or neck atopic dermatitis: results from a decentralized, randomized phase 2 clinical trial.
    J Dermatolog Treat · 2025 · PMID 40132224 · NCT05127421

Lymphohistiocytosis, Hemophagocytic (10)

  • A study of ruxolitinib response-based stratified treatment for pediatric hemophagocytic lymphohistiocytosis.
    Blood · 2022 · PMID 35344583 · NCT05491304
  • Simple Evaluation of Clinical Situation and Subtypes of Pediatric Hemophagocytic Lymphohistiocytosis by Cytokine Patterns.
    Front Immunol · 2022 · PMID 35296096 · NCT05491304
  • Dilemmas in diagnosis and management of hemophagocytic lymphohistiocytosis in children.
    World J Pediatr · 2021 · PMID 31506890 · NCT05491304
  • Ruxolitinib-combined doxorubicin-etoposide-methylprednisolone regimen as a salvage therapy for refractory/relapsed haemophagocytic lymphohistiocytosis: a single-arm, multicentre, phase 2 trial.
    Br J Haematol · 2021 · PMID 33559893 · NCT05491304
  • Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial.
    Lancet Haematol · 2019 · PMID 31537486 · NCT02400463

Publications by journal

Trial-results highlights

In studies of primary myelofibrosis, treatment with Ruxolitinib showed specific outcomes. In NCT00934544, the percentage of participants with at least 35% reduction in spleen volume from baseline at week 48 was 28.5 Percentage of Participants in the Ruxolitinib arm, compared to 0 Percentage of Participants in the Best Available Therapy arm. Another study, NCT00952289, reported that 65 participants in the Ruxolitinib arm achieved a ≥ 35% reduction in spleen volume from baseline to week 24, while 1 participant in the Placebo arm achieved this. In the Simplify 1 study (NCT01969838), which assessed splenic response rate at week 24, the Ruxolitinib arm included 153 Participants and 64 Participants, while the Momelotinib arm included 57 Participants and 158 Participants.

For polycythemia vera, results from NCT01243944 showed that 22.7 percentage of participants in the Ruxolitinib arm achieved a primary response at week 32, compared to 0.9 percentage of participants in the Best Available Therapy arm. In NCT01632904, assessing a ≥ 50% improvement in Total Symptom Score-Cytokine (TSS-C) at week 16, 43.4 Percentage of participants in the Ruxolitinib arm achieved this, versus 29.6 Percentage of participants in the Hydroxyurea arm. For myeloproliferative disorders, the RESPONSE-2 study (NCT02038036) found that 46 Participants in the Ruxolitinib arm achieved hematocrit control at week 28, compared to 14 Participants in the Best Available Therapy arm.

In a study of pancreatic neoplasms (NCT02117479), overall survival was assessed. The Ruxolitinib Plus Capecitabine arm included 113 Participants and 48 Participants, while the Placebo Plus Capecitabine arm included 124 Participants and 36 Participants. All values presented here are sourced from primary registry reporting; individual papers should be consulted for clinical decisions.

All Ruxolitinib publications (377)

2026 (13 papers)

  1. Efficacy and safety of ruxolitinib for graft-versus-host disease prophylaxis in patients with aplastic anemia undergoing PBSC-only allogeneic stem cell transplantation: a prospective phase II study.
    Zhang X, Pan L, Zhao Y, et al. · Exp Hematol Oncol · 2026 · Derived
    PubMed: PMID 41796372 · NCT05914714
  2. Assessment of flonoltinib maleate versus ruxolitinib phosphate in intermediate- to high-risk myelofibrosis (FMF-02): study protocol for a multicenter, randomized, open-label phase IIB trial.
    Yang L, Tan K, Liang R, et al. · Ther Adv Hematol · 2026 · Derived
    PubMed: PMID 41883618 · NCT06457425
  3. Preliminary Safety and Efficacy of Navitoclax Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis From the Multicenter, Open-Label, Phase 2 Study (REFINE).
    Passamonti F, Foran JM, Tandra A, et al. · Hematol Oncol · 2026 · Derived
    PubMed: PMID 41846295 · NCT03222609 (REFINE) · Primary Myelofibrosis
  4. Association Between Transfusion Status, Hemoglobin Levels, and Patient-Reported Outcomes in Myelofibrosis: A Post Hoc Clinical Trial Analysis.
    Mesa R, Palmer JM, Palandri F, et al. · Cancer Med · 2026 · Derived
    PubMed: PMID 41958363 · NCT01969838 (Simplify 1) · Primary Myelofibrosis
  5. Phase 1b study of ABBV-744, a novel, selective BET inhibitor, as monotherapy for patients with myelofibrosis.
    Mascarenhas J, Fogliatto L, Green S, et al. · Blood Adv · 2026 · Derived
    PubMed: PMID 41843794 · NCT04454658 · Primary Myelofibrosis
  6. Clinical considerations for ruxolitinib in the treatment of steroid-refractory acute graft-versus-host disease (GVHD) and steroid-refractory or -dependent chronic GVHD: a plain language summary.
    Mahmoudjafari Z, Bhatt V, Xue Z, et al. · Ther Adv Hematol · 2026 · Derived
    PubMed: PMID 42180389 · NCT03112603 · Graft vs Host Disease
  7. Safety and Tolerability of Ruxolitinib Cream in Adolescents with Mild-to-Moderate Atopic Dermatitis: Results From a 1-Year, Phase III, Open-Label Study.
    Joyce JC, Hong HC, Siri DD, et al. · Am J Clin Dermatol · 2026 · Derived
    PubMed: PMID 42201487 · NCT05456529 · Dermatitis, Atopic
  8. A randomized, multicenter phase II trial to compare prophylaxis of graft versus host disease with tacrolimus and mycophenolate mofetil versus ruxolitinib after post-transplant cyclophosphamide.
    Moiseev I, Drokov M, Kitaeva Y, et al. · Transplant Cell Ther · 2026 · Derived
    PubMed: PMID 42066960 · NCT04669210 (PTCyRuxo) · Graft vs Host Disease
  9. Multiarm multistage randomised controlled trial of inflammatory signal inhibitors (MATIS) for patients hospitalised with COVID-19 pneumonia during the UK pandemic.
    Hazell L, Pillay C, Cornelius V, et al. · BMJ Open · 2026 · Derived
    PubMed: PMID 41644167 · NCT04581954 (MATIS) · COVID-19
  10. Ruxolitinib treatment in patients with polycythemia vera reduces JAK2 variant allele frequency and improves symptom burden and hematocrit control.
    Harrison CN, Kiladjian JJ, Hamer-Maansson JE, et al. · Ther Adv Hematol · 2026 · Derived
    PubMed: PMID 41890273 · NCT01243944 · Polycythemia Vera
  11. Results of a phase 1 trial testing ruxolitinib plus venetoclax in patients with relapsed/refractory acute myeloid leukemia.
    Borate U, Tognon CE, Madanat YF, et al. · Blood Neoplasia · 2026 · Derived
    PubMed: PMID 42007254 · NCT03874052 · Leukemia, Myeloid, Acute
  12. Ruxolitinib Cream As-Needed Monotherapy Demonstrates Sustained Disease and Symptom Control in Patients with Mild to Moderate Atopic Dermatitis: Pooled Analysis from Two Phase 3 Studies.
    Blauvelt A, Kircik L, Simpson EL, et al. · Dermatol Ther (Heidelb) · 2026 · Derived
    PubMed: PMID 41678112 · NCT03745651 · Dermatitis, Atopic
  13. Selinexor plus ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis: a multicenter, open-label, phase 1 study.
    Ali H, Mohan S, Kishtagari A, et al. · Blood Adv · 2026 · Derived
    PubMed: PMID 41785311 · NCT04562389 (SENTRY) · Primary Myelofibrosis

2025 (25 papers)

  1. Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial.
    Rampal RK, Grosicki S, Chraniuk D, et al. · Nat Med · 2025 · Trial result
    PubMed: PMID 40065169 · NCT04603495 (MANIFEST-2) · Primary Myelofibrosis
  2. Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study.
    Zeiser R, Russo D, Ram R, et al. · J Clin Oncol · 2025 · Derived
    PubMed: PMID 40561385 · NCT03112603 · Graft vs Host Disease
  3. Ruxolitinib for Emergency Treatment of COVID-19-Associated Cytokine Storm: Findings From an Expanded Access Study.
    Weinstein J, Jagan N, Lorthridge-Jackson S, et al. · Clin Respir J · 2025 · Derived
    PubMed: PMID 40197709 · NCT04355793 · COVID-19
  4. Ruxolitinib and decitabine plus a busulfan-cyclophosphamide conditioning regimen for relapse prophylaxis in patients with high-risk acute myeloid leukemia or myelodysplastic syndromes.
    Wei Y, Luan S, Wang L, et al. · Front Immunol · 2025 · Derived
    PubMed: PMID 40901473 · NCT04582604
  5. Leveraging epigenetic alterations in pancreatic ductal adenocarcinoma for clinical applications.
    Tost J, Ak-Aksoy S, Campa D, et al. · Semin Cancer Biol · 2025 · Derived
    PubMed: PMID 39863139 · NCT03878524 · Primary Myelofibrosis
  6. A Maximum-Use Trial of Ruxolitinib Cream in Children Aged 2-11 Years with Moderate to Severe Atopic Dermatitis.
    Stein Gold L, Bissonnette R, Forman S, et al. · Am J Clin Dermatol · 2025 · Derived
    PubMed: PMID 39760983 · NCT05034822 · Dermatitis, Atopic
  7. Ruxolitinib Cream Monotherapy Improved Symptoms and Quality of Life in Adults and Adolescents with Mild-to-Moderate Atopic Dermatitis: Patient-Reported Outcomes from Two Phase III Studies.
    Simpson EL, Augustin M, Thaçi D, et al. · Am J Clin Dermatol · 2025 · Derived
    PubMed: PMID 39546129 · NCT03745638 · Dermatitis, Atopic
  8. Efficacy and Safety of Ruxolitinib Cream in Vitiligo by Patient Characteristic Subgroups: Descriptive Pooled Analysis From Two Phase 3 Studies.
    Seneschal J, Wolkerstorfer A, Desai SR, et al. · Dermatol Ther (Heidelb) · 2025 · Derived
    PubMed: PMID 40156697 · NCT04057573 · Vitiligo
  9. ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosis.
    Ross DM, Heidel FH, Perkins AC, et al. · Blood Adv · 2025 · Derived
    PubMed: PMID 40334082 · NCT04097821 (ADORE) · Primary Myelofibrosis
  10. Long-Term Integrated Safety Summary of Ruxolitinib Cream in Phase 3 Clinical Trials of Patients with Vitiligo.
    Rosmarin D, Pandya AG, Passeron T, et al. · Dermatol Ther (Heidelb) · 2025 · Derived
    PubMed: PMID 41125994 · NCT04530344 · Vitiligo
  11. Addition of navitoclax to ruxolitinib for patients with myelofibrosis with progression or suboptimal response.
    Pemmaraju N, Somervaille TCP, Palandri F, et al. · Blood Neoplasia · 2025 · Derived
    PubMed: PMID 40454409 · NCT03222609 (REFINE) · Primary Myelofibrosis
  12. Ruxolitinib Versus Best Available Therapy in Patients With Steroid-Refractory Acute Graft-Versus-Host Disease: Final Analysis From the Randomized Phase III REACH2 Trial.
    Mohty M, Socié G, Szer J, et al. · J Clin Oncol · 2025 · Derived
    PubMed: PMID 41092247 · NCT02913261 (REACH2) · Graft vs Host Disease
  13. Time Without Transfusion Reliance (TWiTR): Integrating Survival Quality Into Myelofibrosis Treatment Strategies Based on the Phase 3 SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM Trials.
    Mesa RA, Talpaz M, Mazerolle F, et al. · EJHaem · 2025 · Derived
    PubMed: PMID 40535755 · NCT01969838 (Simplify 1) · Primary Myelofibrosis
  14. Selinexor plus ruxolitinib in JAK inhibitor treatment-naïve myelofibrosis: SENTRY Phase 3 study design.
    Mascarenhas J, Maher K, Rampal R, et al. · Future Oncol · 2025 · Derived
    PubMed: PMID 39911057 · NCT04562389 (SENTRY) · Primary Myelofibrosis
  15. Impact of concomitant azoles on ruxolitinib treatment in patients with GVHD: post hoc analyses of REACH2 and REACH3.
    Mahmoudjafari Z, Kintsch E, Xue Z, et al. · Blood Adv · 2025 · Derived
    PubMed: PMID 40472328 · NCT02913261 (REACH2) · Graft vs Host Disease
  16. Longitudinal Assessment of Transfusion Intensity in Patients With JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated With Momelotinib.
    Harrison CN, Mesa R, Talpaz M, et al. · Clin Lymphoma Myeloma Leuk · 2025 · Derived
    PubMed: PMID 39516087 · NCT01969838 (Simplify 1) · Primary Myelofibrosis
  17. Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT.
    DeFilipp Z, Kim HT, Knight LW, et al. · Blood · 2025 · Derived
    PubMed: PMID 40106768 · NCT03286530 · Leukemia, Myeloid, Acute
  18. A phase 2 multicenter trial of ruxolitinib to treat bronchiolitis obliterans syndrome after allogeneic HCT.
    DeFilipp Z, Kim HT, Cheng GS, et al. · Blood Adv · 2025 · Derived
    PubMed: PMID 39365992 · NCT03674047
  19. Ruxolitinib cream monotherapy for facial and/or neck atopic dermatitis: results from a decentralized, randomized phase 2 clinical trial.
    Chiesa Fuxench ZC, Lai Z, Kuo Y, et al. · J Dermatolog Treat · 2025 · Derived
    PubMed: PMID 40132224 · NCT05127421 · Dermatitis, Atopic
  20. Autonomous artificial intelligence prescribing a drug to prevent severe acute graft-versus-host disease in HLA-haploidentical transplants.
    Chen J, Cao Y, Feng Y, et al. · Nat Commun · 2025 · Derived
    PubMed: PMID 40998766 · NCT05600855
  21. Allogeneic hematopoietic cell transplantation with a combination of posttransplantation bendamustine and cyclophosphamide in refractory myeloid neoplasms.
    Moiseev I, Bondarenko S, Vlasova Y, et al. · Cancer · 2025 · Background
    PubMed: PMID 40372957 · NCT07238712 (APTBCy) · Graft vs Host Disease
  22. Toward Improving Initial Therapy of Acute Graft Versus Host Disease.
    Mehta AK, Koreth J · Am J Hematol · 2025 · Background
    PubMed: PMID 39936555 · NCT07509749 (GVHD) · Graft vs Host Disease
  23. Recent advances in acute gastrointestinal graft versus host disease (aGvHD): aspects of steroid-resistant disease.
    Kujawska J, Zeiser R, Gil L, et al. · Ann Hematol · 2025 · Background
    PubMed: PMID 39207560 · NCT07340723 (GVHD)
  24. Comparable outcomes after busulfan- or treosulfan-based conditioning for allo-HSCT in children with ALL: results of FORUM.
    Kalwak K, Moser LM, Pötschger U, et al. · Blood Adv · 2025 · Background
    PubMed: PMID 39602342 · NCT07297914 (FORUM2) · Graft vs Host Disease
  25. Erythropoietin Receptor Signaling Through STAT3 Is Required For Glioma Stem Cell Maintenance.
    Cao Y, Lathia JD, Eyler CE, et al. · Genes Cancer · 2025 · Background
    PubMed: PMID 20657792 · NCT06991101 · Glioblastoma

2024 (21 papers)

  1. GSK-3β inhibitor, 9-ING-41, reduces cell viability and halts proliferation of B-cell lymphoma cell lines as a single agent and in combination with novel agents.
    Karmali R, Chukkapalli V, Gordon LI, et al. · Oncotarget · 2024 · Trial result
    PubMed: PMID 29383130 · NCT04218071 · Primary Myelofibrosis
  2. Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results.
    Yacoub A, Borate U, Rampal RK, et al. · Blood Adv · 2024 · Derived
    PubMed: PMID 38290135 · NCT02718300 · Primary Myelofibrosis
  3. Addition of ruxolitinib and decitabine to modified busulfan/cyclophosphamide conditioning regimen for prophylaxis relapse in high-risk acute myeloid leukemia: the phase 2 prospective study.
    Wei Y, Qian K, Le N, et al. · Ann Hematol · 2024 · Derived
    PubMed: PMID 39243311 · NCT04582604
  4. Results from phase 1 of the MANIFEST clinical trial to evaluate the safety and tolerability of pelabresib in patients with myeloid malignancies.
    Stein EM, Fathi AT, Harb WA, et al. · Leuk Lymphoma · 2024 · Derived
    PubMed: PMID 38259250 · NCT02158858 · Primary Myelofibrosis
  5. Ruxolitinib Cream in Adolescents/Adults with Atopic Dermatitis Meeting Severity Thresholds for Systemic Therapy: Exploratory Analysis of Pooled Results from Two Phase 3 Studies.
    Simpson EL, Kircik L, Blauvelt A, et al. · Dermatol Ther (Heidelb) · 2024 · Derived
    PubMed: PMID 38995504 · NCT03745651 · Dermatitis, Atopic
  6. TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer.
    Lynce F, Stevens LE, Li Z, et al. · Breast Cancer Res · 2024 · Derived
    PubMed: PMID 38297352 · NCT02876302 · Breast Neoplasms
  7. Ruxolitinib for pediatric patients with treatment-naïve and steroid-refractory acute graft-versus-host disease: the REACH4 study.
    Locatelli F, Kang HJ, Bruno B, et al. · Blood · 2024 · Derived
    PubMed: PMID 39046767 · NCT03491215 · Graft vs Host Disease
  8. Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study.
    Landen CN, Buckanovich RJ, Sill MW, et al. · J Clin Oncol · 2024 · Derived
    PubMed: PMID 38776484 · NCT02713386 · Fallopian Tube Neoplasms
  9. Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Han MK, Antila M, Ficker JH, et al. · Lancet Rheumatol · 2024 · Derived
    PubMed: PMID 35368384 · NCT04362137 (RUXCOVID) · COVID-19
  10. Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial.
    Gupta V, Oh S, Devos T, et al. · Leuk Lymphoma · 2024 · Derived
    PubMed: PMID 38501751 · NCT01969838 (Simplify 1) · Primary Myelofibrosis
  11. Targeting anemia in myeloid neoplasms.
    Gangat N, Tefferi A · Am J Hematol · 2024 · Derived
    PubMed: PMID 38837732 · NCT04455841 · Anemia
  12. Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies.
    Eichenfield LF, Simpson EL, Papp K, et al. · Am J Clin Dermatol · 2024 · Derived
    PubMed: PMID 38698175 · NCT03745638 · Dermatitis, Atopic
  13. Ruxolitinib plus steroids for acute graft versus host disease: a multicenter, randomized, phase 3 trial.
    Dou L, Zhao Y, Yang J, et al. · Signal Transduct Target Ther · 2024 · Derived
    PubMed: PMID 39438467 · NCT04061876
  14. Ruxolitinib Rapidly Reduces Acute Respiratory Distress Syndrome in COVID-19 Disease. Analysis of Data Collection From RESPIRE Protocol.
    Capochiani E, Frediani B, Iervasi G, et al. · Front Med (Lausanne) · 2024 · Derived
    PubMed: PMID 32850921 · NCT04361903 (RESPIRE) · COVID-19
  15. Efficacy and Safety of Ruxolitinib Cream in Atopic Dermatitis Based on Previous Medication History.
    Blauvelt A, Kallender H, Sturm D, et al. · Dermatol Ther (Heidelb) · 2024 · Derived
    PubMed: PMID 39375281 · NCT03745651 · Dermatitis, Atopic
  16. Psychometric Evaluation of the Facial and Total Vitiligo Area Scoring Index Instruments in the TRuE-V Phase 3 Studies.
    Bibeau K, Butler K, Wang M, et al. · Dermatol Ther (Heidelb) · 2024 · Derived
    PubMed: PMID 39078582 · NCT04057573 · Vitiligo
  17. A Multicenter Phase II Trial of Ruxolitinib for Treatment of Corticosteroid Refractory Sclerotic Chronic Graft-Versus-Host Disease.
    Bhatt VR, Shostrom VK, Choe HK, et al. · J Clin Oncol · 2024 · Derived
    PubMed: PMID 39151112 · NCT03616184 · Graft vs Host Disease
  18. A Phase I Trial Evaluating the Addition of Lenalidomide to Patients with Relapsed/Refractory Multiple Myeloma Progressing on Ruxolitinib and Methylprednisolone.
    Berenson JR, Limon A, Rice S, et al. · Target Oncol · 2024 · Derived
    PubMed: PMID 38643346 · NCT03110822 · Multiple Myeloma
  19. Anti-T-lymphocyte globulin exposure is associated with acute graft-versus-host disease and relapse in pediatric acute lymphoblastic leukemia patients undergoing hematopoietic stem cell transplantation: a multinational prospective study.
    Oostenbrink LVE, Von Asmuth EGJ, Jol-van der Zijde CM, et al. · Haematologica · 2024 · Background
    PubMed: PMID 38721739 · NCT07297914 (FORUM2) · Graft vs Host Disease
  20. Treatment Patterns and Clinical Outcomes of Patients with Moderate to Severe Acute Graft-Versus-Host Disease: A Multicenter Chart Review Study.
    Michonneau D, Devillier R, Keränen M, et al. · Hematol Rep · 2024 · Background
    PubMed: PMID 38804281 · NCT07509749 (GVHD) · Graft vs Host Disease
  21. Low rate of nonrelapse mortality in under-4-year-olds with ALL given chemotherapeutic conditioning for HSCT: a phase 3 FORUM study.
    Bader P, Pötschger U, Dalle JH, et al. · Blood Adv · 2024 · Background
    PubMed: PMID 37738088 · NCT07297914 (FORUM2) · Graft vs Host Disease

2023 (26 papers)

  1. Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study.
    Miklos DB, Abu Zaid M, Cooney JP, et al. · J Clin Oncol · 2023 · Trial result
    PubMed: PMID 36608310 · NCT06756061 (FRONTJAK-001) · Graft vs Host Disease
  2. Anti-CD3/CD7 immunoconjugate (T-Guard) for severe, steroid-refractory GVHD: final report of BMT CTN 2002.
    Meyers G, Hamadani M, Martens M, et al. · Bone Marrow Transplant · 2023 · Trial result
    PubMed: PMID 37749187 · NCT04934670 (2002) · Lymphoma, Follicular
  3. Exploration of efficacy and safety of combined therapy of basiliximab with ruxolitinib for grade 3-4 steroid-refractory acute graft-versus-host disease: a registered clinical trial (NCT05021276).
    Zhou F, Pan T, Li X, et al. · Bone Marrow Transplant · 2023 · Derived
    PubMed: PMID 37253803 · NCT05021276
  4. Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials.
    Verstovsek S, Mesa R, Gupta V, et al. · Blood Adv · 2023 · Derived
    PubMed: PMID 37042865 · NCT01969838 (Simplify 1) · Primary Myelofibrosis
  5. Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial.
    Verstovsek S, Foltz L, Gupta V, et al. · Haematologica · 2023 · Derived
    PubMed: PMID 37165840 · NCT01981850 · Primary Myelofibrosis
  6. Challenges for Drug Repurposing in the COVID-19 Pandemic Era.
    Sultana J, Crisafulli S, Gabbay F, et al. · Front Pharmacol · 2023 · Derived
    PubMed: PMID 33240091 · NCT04348695 (Ruxo-Sim-20) · COVID-19
  7. Prognostic value of blood biomarkers in steroid-refractory or steroid-dependent acute graft-versus-host disease: a REACH2 analysis.
    Socié G, Niederwieser D, von Bubnoff N, et al. · Blood · 2023 · Derived
    PubMed: PMID 36827620 · NCT02913261 (REACH2) · Graft vs Host Disease
  8. Phase 1/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic Malignancies.
    Patel MR, Donnellan W, Byrne M, et al. · Clin Lymphoma Myeloma Leuk · 2023 · Derived
    PubMed: PMID 37290996 · NCT02587598 · Primary Myelofibrosis
  9. Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: Results from two phase 3 studies.
    Papp K, Szepietowski JC, Kircik L, et al. · J Am Acad Dermatol · 2023 · Derived
    PubMed: PMID 36574595 · NCT03745651 · Dermatitis, Atopic
  10. Prospects of early therapeutic interventions for indolent adult T-cell leukemia/lymphoma based on the chronic lymphocytic leukemia progression model.
    Ohmoto A, Fuji S · Blood Rev · 2023 · Derived
    PubMed: PMID 36828681 · NCT01712659 · Leukemia-Lymphoma, Adult T-Cell
  11. MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis.
    Mascarenhas J, Kremyanskaya M, Patriarca A, et al. · J Clin Oncol · 2023 · Derived
    PubMed: PMID 36881782 · NCT02158858 · Primary Myelofibrosis
  12. Nodal peripheral T-cell lymphoma: Chemotherapy-free management, are we there yet?
    Macapagal SC, Bennani NN · Blood Rev · 2023 · Derived
    PubMed: PMID 36898933 · NCT03017820 · Leukemia, Myeloid, Acute
  13. Safety, pharmacokinetics, and efficacy of ruxolitinib cream in children and adolescents with atopic dermatitis.
    Leung DYM, Paller AS, Zaenglein AL, et al. · Ann Allergy Asthma Immunol · 2023 · Derived
    PubMed: PMID 36586583 · NCT03257644 · Dermatitis, Atopic
  14. Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group.
    Koschmieder S, Isfort S, Wolf D, et al. · Ann Hematol · 2023 · Derived
    PubMed: PMID 36564535 · NCT02577926 (Ruxo-BEAT) · Polycythemia Vera
  15. Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study.
    Isfort S, Manz K, Teichmann LL, et al. · Ann Hematol · 2023 · Derived
    PubMed: PMID 37592092 · NCT02577926 (Ruxo-BEAT) · Polycythemia Vera
  16. Baseline Levels of Circulating Inflammatory Biomarkers Stratify Patients with Vitiligo Who Significantly Repigment after Treatment with Ruxolitinib Cream.
    Howell MD, Kuo FI, Rumberger B, et al. · JID Innov · 2023 · Derived
    PubMed: PMID 37840766 · NCT03099304 · Vitiligo
  17. The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial.
    Hammersen J, Birndt S, Döhner K, et al. · Leukemia · 2023 · Derived
    PubMed: PMID 37507425 · NCT04338958 (RuxCoFlam) · COVID-19
  18. Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis.
    Gupta V, Mascarenhas J, Kremyanskaya M, et al. · Blood Adv · 2023 · Derived
    PubMed: PMID 37530627 · NCT02158858 · Primary Myelofibrosis
  19. Randomized phase II clinical trial of ruxolitinib plus simvastatin in COVID19 clinical outcome and cytokine evolution.
    Garcia-Donas J, Martínez-Urbistondo D, Velázquez Kennedy K, et al. · Front Immunol · 2023 · Derived
    PubMed: PMID 37143685 · NCT04348695 (Ruxo-Sim-20) · COVID-19
  20. Impact of Ruxolitinib Cream on Work Productivity and Activity Impairment and Associated Indirect Costs in Patients with Atopic Dermatitis: Pooled Results From Two Phase III Studies.
    Bloudek L, Eichenfield LF, Silverberg JI, et al. · Am J Clin Dermatol · 2023 · Derived
    PubMed: PMID 36264430 · NCT03745651 · Dermatitis, Atopic
  21. Ruxolitinib and methylprednisolone for treatment of patients with relapsed/refractory multiple myeloma.
    Berenson JR, Martinez D, Safaie T, et al. · Br J Haematol · 2023 · Derived
    PubMed: PMID 36482815 · NCT03110822 · Multiple Myeloma
  22. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2.
    Zhou Y, Hou Y, Shen J, et al. · Cell Discov · 2023 · Background
    PubMed: PMID 32194980 · NCT04414098 · COVID-19
  23. The effect of granulocyte-colony stimulating factor, decitabine, and busulfan-cyclophosphamide versus busulfan-cyclophosphamide conditioning on relapse in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia evolving from myelodysplastic syndrome undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised, phase 3 trial.
    Xuan L, Dai M, Jiang E, et al. · Lancet Haematol · 2023 · Background
    PubMed: PMID 36702138 · NCT07101588
  24. First-in-Human Intrathoracic Implantation of Multidrug-Eluting Microdevices for In Situ Chemotherapeutic Sensitivity Testing as Proof of Concept in Nonsmall Cell Lung Cancer.
    Tsai LL, Phillips WW, Hung YP, et al. · Ann Surg · 2023 · Background
    PubMed: PMID 35129472 · NCT07352566 · Dermatitis, Atopic
  25. Intratumoral drug-releasing microdevices allow in situ high-throughput pharmaco phenotyping in patients with gliomas.
    Peruzzi P, Dominas C, Fell G, et al. · Sci Transl Med · 2023 · Background
    PubMed: PMID 37672566 · NCT07352566 · Dermatitis, Atopic
  26. Features, Evaluation, and Treatment of Coronavirus (COVID-19)
    Features, Evaluation, and Treatment of Coronavirus (COVID-19) · 2023 · Background
    PubMed: PMID 32150360 · NCT04414098 · COVID-19

2022 (30 papers)

  1. Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis.
    Harrison CN, Gupta VK, Gerds AT, et al. · Future Oncol · 2022 · Trial result
    PubMed: PMID 35950489 · NCT04603495 (MANIFEST-2) · Primary Myelofibrosis
  2. Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma.
    Cook J, Peng KW, Witzig TE, et al. · Blood Adv · 2022 · Trial result
    PubMed: PMID 35175355 · NCT03017820 · Leukemia, Myeloid, Acute
  3. [Kinetics of MDSC in Patients Treated Steroids-Ruxolitinib as the First Line Therapy for aGVHD].
    Yang JJ, Peng B, Fang S, et al. · Zhongguo Shi Yan Xue Ye Xue Za Zhi · 2022 · Derived
    PubMed: PMID 35123640 · NCT04061876
  4. Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis and Low Platelet Counts (50 - 100 × 109/L): Final Analysis of an Open-Label Phase 2 Study.
    Talpaz M, Prchal J, Afrin L, et al. · Clin Lymphoma Myeloma Leuk · 2022 · Derived
    PubMed: PMID 34911667 · NCT01348490 · Myeloproliferative Disorders
  5. Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo.
    Rosmarin D, Passeron T, Pandya AG, et al. · N Engl J Med · 2022 · Derived
    PubMed: PMID 36260792 · NCT04057573 · Vitiligo
  6. Randomized Phase 3 Trial of Ruxolitinib for COVID-19-Associated Acute Respiratory Distress Syndrome.
    Rein L, Calero K, Shah R, et al. · Crit Care Med · 2022 · Derived
    PubMed: PMID 36226977 · NCT04377620 · COVID-19
  7. Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study.
    Pemmaraju N, Garcia JS, Potluri J, et al. · Lancet Haematol · 2022 · Derived
    PubMed: PMID 35576960 · NCT03222609 (REFINE) · Primary Myelofibrosis
  8. Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study.
    Passamonti F, Palandri F, Saydam G, et al. · Lancet Haematol · 2022 · Derived
    PubMed: PMID 35597252 · NCT02038036 (RESPONSE-2) · Myeloproliferative Disorders
  9. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies.
    Papp K, Szepietowski JC, Kircik L, et al. · J Am Acad Dermatol · 2022 · Derived
    PubMed: PMID 33957195 · NCT03745651 · Dermatitis, Atopic
  10. A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas.
    Moskowitz AJ, Ghione P, Jacobsen E, et al. · Blood · 2022 · Derived
    PubMed: PMID 34653242 · NCT02974647 · Recurrence
  11. Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults With Human Immunodeficiency Virus.
    Marconi VC, Moser C, Gavegnano C, et al. · Clin Infect Dis · 2022 · Derived
    PubMed: PMID 33693561 · NCT02475655 · HIV Infections
  12. FDA Approval Summary: Ruxolitinib for Treatment of Chronic Graft-Versus-Host Disease after Failure of One or Two Lines of Systemic Therapy.
    Le RQ, Wang X, Zhang H, et al. · Oncologist · 2022 · Derived
    PubMed: PMID 35363318 · NCT03112603 · Graft vs Host Disease
  13. Janus kinase inhibitors for the treatment of COVID-19.
    Kramer A, Prinz C, Fichtner F, et al. · Cochrane Database Syst Rev · 2022 · Derived
    PubMed: PMID 35695334 · NCT04331665 · COVID-19
  14. Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy.
    Harrison CN, Garcia JS, Somervaille TCP, et al. · J Clin Oncol · 2022 · Derived
    PubMed: PMID 35180010 · NCT03222609 (REFINE) · Primary Myelofibrosis
  15. Efficacy and safety of ruxolitinib in patients with myelofibrosis and low platelet count (50 × 109/L to <100 × 109/L) at baseline: the final analysis of EXPAND.
    Guglielmelli P, Kiladjian JJ, Vannucchi AM, et al. · Ther Adv Hematol · 2022 · Derived
    PubMed: PMID 36105914 · NCT01317875 · Primary Myelofibrosis
  16. Ruxolitinib-corticosteroid as first-line therapy for newly diagnosed high-risk acute graft versus host disease: study protocol for a multicenter, randomized, phase II controlled trial.
    Dou L, Peng B, Li X, et al. · Trials · 2022 · Derived
    PubMed: PMID 35668528 · NCT04061876
  17. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Coadministered Ruxolitinib and Artemether-Lumefantrine in Healthy Adults.
    Chughlay MF, Barnes KI, El Gaaloul M, et al. · Antimicrob Agents Chemother · 2022 · Derived
    PubMed: PMID 34694880 · NCT04456634 · Malaria
  18. A Maximum-Use Trial of Ruxolitinib Cream in Adolescents and Adults with Atopic Dermatitis.
    Bissonnette R, Call RS, Raoof T, et al. · Am J Clin Dermatol · 2022 · Derived
    PubMed: PMID 35368221 · NCT03920852 · Dermatitis, Atopic
  19. A phase 1 study of ruxolitinib, steroids and lenalidomide for relapsed/refractory multiple myeloma patients.
    Berenson JR, Kim C, Bujarski S, et al. · Hematol Oncol · 2022 · Derived
    PubMed: PMID 35946431 · NCT03110822 · Multiple Myeloma
  20. Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study.
    Ali H, Tsai NC, Synold T, et al. · Blood Adv · 2022 · Derived
    PubMed: PMID 34581764 · NCT02917096 · Primary Myelofibrosis
  21. A study of ruxolitinib response-based stratified treatment for pediatric hemophagocytic lymphohistiocytosis.
    Zhang Q, Zhao YZ, Ma HH, et al. · Blood · 2022 · Background
    PubMed: PMID 35344583 · NCT05491304 · Lymphohistiocytosis, Hemophagocytic
  22. Simple Evaluation of Clinical Situation and Subtypes of Pediatric Hemophagocytic Lymphohistiocytosis by Cytokine Patterns.
    Xu XJ, Luo ZB, Song H, et al. · Front Immunol · 2022 · Background
    PubMed: PMID 35296096 · NCT05491304 · Lymphohistiocytosis, Hemophagocytic
  23. A multiplex implantable microdevice assay identifies synergistic combinations of cancer immunotherapies and conventional drugs.
    Tatarova Z, Blumberg DC, Korkola JE, et al. · Nat Biotechnol · 2022 · Background
    PubMed: PMID 35788566 · NCT07352566 · Dermatitis, Atopic
  24. High Response Rate and Corticosteroid Sparing with Arsenic Trioxide-Based First-Line Therapy in Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.
    Rongvaux-Gaïda D, Dupuis M, Poupon J, et al. · Transplant Cell Ther · 2022 · Background
    PubMed: PMID 35830931 · NCT06756061 (FRONTJAK-001) · Graft vs Host Disease
  25. STAT3 Activation as a Predictive Biomarker for Ruxolitinib Response in Head and Neck Cancer.
    Qureshy Z, Li H, Zeng Y, et al. · Clin Cancer Res · 2022 · Background
    PubMed: PMID 35929989 · NCT03153982 · Squamous Cell Carcinoma of Head and Neck
  26. The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes.
    Moyo TK, Mendler JH, Itzykson R, et al. · BMC Cancer · 2022 · Background
    PubMed: PMID 36153475 · NCT04061421 (ABNL-MARRO)
  27. Decitabine-Intensified Modified Busulfan/Cyclophosphamide Conditioning Regimen Improves Survival in Acute Myeloid Leukemia Patients Undergoing Related Donor Hematopoietic Stem Cell Transplantation: A Propensity Score Matched Analysis.
    Li Z, Shi W, Lu X, et al. · Front Oncol · 2022 · Background
    PubMed: PMID 35371981 · NCT07101588
  28. A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease.
    Lazaryan A, Lee S, Arora M, et al. · Blood Adv · 2022 · Background
    PubMed: PMID 34649279 · NCT06756061 (FRONTJAK-001) · Graft vs Host Disease
  29. Disease progression, treatments, hospitalization, and clinical outcomes in acute GVHD: a multicenter chart review.
    Holtan SG, Yu J, Choe HK, et al. · Bone Marrow Transplant · 2022 · Background
    PubMed: PMID 35908108 · NCT07340723 (GVHD)
  30. Updates in chronic graft-versus-host disease.
    Hamilton BK · Hematology Am Soc Hematol Educ Program · 2022 · Background
    PubMed: PMID 34889364 · NCT06756061 (FRONTJAK-001) · Graft vs Host Disease

2021 (34 papers)

  1. Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease.
    Zeiser R, Polverelli N, Ram R, et al. · N Engl J Med · 2021 · Trial result
    PubMed: PMID 34260836 · NCT06756061 (FRONTJAK-001) · Graft vs Host Disease
  2. Steroid-refractory chronic graft-versus-host disease: treatment options and patient management.
    Wolff D, Fatobene G, Rocha V, et al. · Bone Marrow Transplant · 2021 · Trial result
    PubMed: PMID 34218265 · NCT05663827 · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  3. FDA Approval Summary: Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease.
    Przepiorka D, Luo L, Subramaniam S, et al. · Oncologist · 2021 · Trial result
    PubMed: PMID 32043777 · NCT05663827 · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  4. Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.
    Dao KT, Gotlib J, Deininger MMN, et al. · J Clin Oncol · 2021 · Trial result
    PubMed: PMID 31880950 · NCT02092324 · Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
  5. Impact of graft-versus-host disease and graft-versus-leukemia effect based on minimal residual disease in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Akahoshi Y, Igarashi A, Fukuda T, et al. · Br J Haematol · 2021 · Trial result
    PubMed: PMID 32119132 · NCT04397367
  6. Eradicating residual chronic myeloid leukaemia: basic research lost in translation.
    Zhao H, Deininger M · Lancet Haematol · 2021 · Derived
    PubMed: PMID 33513367 · NCT03654768 · Leukemia, Myeloid, Chronic-Phase
  7. Effect of Ibrutinib on the IFN Response of Chronic Lymphocytic Leukemia Cells.
    Xia M, Luo TY, Shi Y, et al. · J Immunol · 2021 · Derived
    PubMed: PMID 33067379 · NCT02015208 · Leukemia, Lymphocytic, Chronic, B-Cell
  8. A novel MYC-non-IG fusion in refractory diffuse large B-cell lymphoma.
    Wang C, Althof PA, Bi C, et al. · Br J Haematol · 2021 · Derived
    PubMed: PMID 33942298 · NCT01431209 · Lymphoma, T-Cell
  9. Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial.
    Vergis N, Phillips R, Cornelius V, et al. · Trials · 2021 · Derived
    PubMed: PMID 33845867 · NCT04581954 (MATIS) · COVID-19
  10. Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia.
    Uy GL, Aldoss I, Foster MC, et al. · Blood · 2021 · Derived
    PubMed: PMID 32929488 · NCT02152956 (VOYAGE) · Leukemia
  11. Ruxolitinib versus dexamethasone in hospitalized adults with COVID-19: multicenter matched cohort study.
    Stanevich OV, Fomina DS, Bakulin IG, et al. · BMC Infect Dis · 2021 · Derived
    PubMed: PMID 34937556 · NCT04337359 · COVID-19
  12. Ruxolitinib Cream Has Dual Efficacy on Pruritus and Inflammation in Experimental Dermatitis.
    Scuron MD, Fay BL, Connell AJ, et al. · Front Immunol · 2021 · Derived
    PubMed: PMID 33658996 · NCT03920852 · Dermatitis, Atopic
  13. The janus-kinase inhibitor ruxolitinib in SARS-CoV-2 induced acute respiratory distress syndrome (ARDS).
    Neubauer A, Johow J, Mack E, et al. · Leukemia · 2021 · Derived
    PubMed: PMID 34385593 · NCT04359290 (RuXoCoil) · COVID-19
  14. A Prospective Pilot Study of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide and Ruxolitinib in Patients with Myelofibrosis.
    Morozova EV, Barabanshikova MV, Moiseev IS, et al. · Acta Haematol · 2021 · Derived
    PubMed: PMID 32325461 · NCT02806375 · Primary Myelofibrosis
  15. Colchicine for the treatment of COVID-19.
    Mikolajewska A, Fischer AL, Piechotta V, et al. · Cochrane Database Syst Rev · 2021 · Derived
    PubMed: PMID 34658014 · NCT04403243 (COLORIT) · COVID-19
  16. Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase.
    Mascarenhas JO, Rampal RK, Kosiorek HE, et al. · Blood Adv · 2021 · Derived
    PubMed: PMID 33104796 · NCT02076191 · Myeloproliferative Disorders
  17. Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer.
    Lynce F, Williams JT, Regan MM, et al. · Cancer Chemother Pharmacol · 2021 · Derived
    PubMed: PMID 33585999 · NCT02041429 · Breast Neoplasms
  18. Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies.
    Gong X, Chen X, Kuligowski ME, et al. · Am J Clin Dermatol · 2021 · Derived
    PubMed: PMID 33982267 · NCT03745638 · Dermatitis, Atopic
  19. Efficacy of therapeutic plasma exchange in the treatment of penn class 3 and 4 cytokine release syndrome complicating COVID-19.
    Gluck WL, Callahan SP, Brevetta RA, et al. · Respir Med · 2021 · Derived
    PubMed: PMID 33190086 · NCT04374149 · COVID-19
  20. Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies.
    Falchook G, Rosen S, LoRusso P, et al. · Clin Cancer Res · 2021 · Derived
    PubMed: PMID 31527168 · NCT02711137 · Primary Myelofibrosis
  21. Low-dose ruxolitinib plus steroid in severe SARS-CoV-2 pneumonia.
    D'Alessio A, Del Poggio P, Bracchi F, et al. · Leukemia · 2021 · Derived
    PubMed: PMID 33173161 · NCT04337359 · COVID-19
  22. A Phase I Study of Ruxolitinib, Lenalidomide, and Steroids for Patients with Relapsed/Refractory Multiple Myeloma.
    Berenson JR, To J, Spektor TM, et al. · Clin Cancer Res · 2021 · Derived
    PubMed: PMID 31937615 · NCT03110822 · Multiple Myeloma
  23. JAK Inhibitors: Prospects in Connective Tissue Diseases.
    You H, Xu D, Zhao J, et al. · Clin Rev Allergy Immunol · 2021 · Background
    PubMed: PMID 32222877 · NCT06857240 · Dermatomyositis
  24. Dilemmas in diagnosis and management of hemophagocytic lymphohistiocytosis in children.
    Xu XJ, Tang YM · World J Pediatr · 2021 · Background
    PubMed: PMID 31506890 · NCT05491304 · Lymphohistiocytosis, Hemophagocytic
  25. Ruxolitinib-combined doxorubicin-etoposide-methylprednisolone regimen as a salvage therapy for refractory/relapsed haemophagocytic lymphohistiocytosis: a single-arm, multicentre, phase 2 trial.
    Wang J, Zhang R, Wu X, et al. · Br J Haematol · 2021 · Background
    PubMed: PMID 33559893 · NCT05491304 · Lymphohistiocytosis, Hemophagocytic
  26. JAKs to STATs: A tantalizing therapeutic target in acute myeloid leukemia.
    Venugopal S, Bar-Natan M, Mascarenhas JO, et al. · Blood Rev · 2021 · Background
    PubMed: PMID 31677846 · NCT04582604
  27. Low-dose decitabine as part of a modified Bu-Cy conditioning regimen improves survival in AML patients with active disease undergoing allogeneic hematopoietic stem cell transplantation.
    Tang X, Valdez BC, Ma Y, et al. · Bone Marrow Transplant · 2021 · Background
    PubMed: PMID 33637882 · NCT07101588
  28. Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study.
    Peters C, Dalle JH, Locatelli F, et al. · J Clin Oncol · 2021 · Background
    PubMed: PMID 33332189 · NCT07297914 (FORUM2) · Graft vs Host Disease
  29. Study of Tofacitinib in Refractory Dermatomyositis: An Open-Label Pilot Study of Ten Patients.
    Paik JJ, Casciola-Rosen L, Shin JY, et al. · Arthritis Rheumatol · 2021 · Background
    PubMed: PMID 33258553 · NCT06857240 · Dermatomyositis
  30. Brain and other central nervous system tumor statistics, 2021.
    Miller KD, Ostrom QT, Kruchko C, et al. · CA Cancer J Clin · 2021 · Background
    PubMed: PMID 34427324 · NCT06991101 · Glioblastoma
  31. The New Therapeutic Strategies in Pediatric T-Cell Acute Lymphoblastic Leukemia.
    Lato MW, Przysucha A, Grosman S, et al. · Int J Mol Sci · 2021 · Background
    PubMed: PMID 33925883 · NCT05075681
  32. Effects of ruxolitinib cream on pruritus and quality of life in atopic dermatitis: Results from a phase 2, randomized, dose-ranging, vehicle- and active-controlled study.
    Kim BS, Sun K, Papp K, et al. · J Am Acad Dermatol · 2021 · Background
    PubMed: PMID 32057960 · NCT06857240 · Dermatomyositis
  33. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report.
    DeFilipp Z, Couriel DR, Lazaryan A, et al. · Transplant Cell Ther · 2021 · Background
    PubMed: PMID 34147469 · NCT06756061 (FRONTJAK-001) · Graft vs Host Disease
  34. Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium.
    DeFilipp Z, Alousi AM, Pidala JA, et al. · Blood Adv · 2021 · Background
    PubMed: PMID 34521116 · NCT06756061 (FRONTJAK-001) · Graft vs Host Disease

2020 (37 papers)

  1. The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia.
    Yeshurun M, Weisdorf D, Rowe JM, et al. · Blood Adv · 2020 · Trial result
    PubMed: PMID 30808685 · NCT04397367
  2. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.
    Wu Z, McGoogan JM · JAMA · 2020 · Trial result
    PubMed: PMID 32091533 · NCT04366232 (JAKINCOV) · COVID-19
  3. Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma.
    Wu X, Stenson M, Abeykoon J, et al. · Blood · 2020 · Trial result
    PubMed: PMID 31101621 · NCT04218071 · Primary Myelofibrosis
  4. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial.
    Walker I, Panzarella T, Couban S, et al. · Lancet Haematol · 2020 · Trial result
    PubMed: PMID 31958417 · NCT04397367
  5. Combination Treatment with the GSK-3 Inhibitor 9-ING-41 and CCNU Cures Orthotopic Chemoresistant Glioblastoma in Patient-Derived Xenograft Models.
    Ugolkov A, Qiang W, Bondarenko G, et al. · Transl Oncol · 2020 · Trial result
    PubMed: PMID 28672195 · NCT04218071 · Primary Myelofibrosis
  6. COVID-19: consider cytokine storm syndromes and immunosuppression.
    Mehta P, McAuley DF, Brown M, et al. · Lancet · 2020 · Trial result
    PubMed: PMID 32192578 · NCT04366232 (JAKINCOV) · COVID-19
  7. A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post--polycythemia vera/essential thrombocythemia myelofibrosis (post--PV/ET MF).
    Mascarenhas J, Marcellino BK, Lu M, et al. · Leuk Res · 2020 · Trial result
    PubMed: PMID 31778911 · NCT01693601 (PRIME) · Primary Myelofibrosis
  8. Treatment and unmet needs in steroid-refractory acute graft-versus-host disease.
    Malard F, Huang XJ, Sim JPY, et al. · Leukemia · 2020 · Trial result
    PubMed: PMID 32242050 · NCT05663827 · Precursor Cell Lymphoblastic Leukemia-Lymphoma
  9. 9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer.
    Kuroki H, Anraku T, Kazama A, et al. · Sci Rep · 2020 · Trial result
    PubMed: PMID 31882719 · NCT04218071 · Primary Myelofibrosis
  10. Glycogen Synthase Kinase-3β Inhibition with 9-ING-41 Attenuates the Progression of Pulmonary Fibrosis.
    Jeffers A, Qin W, Owens S, et al. · Sci Rep · 2020 · Trial result
    PubMed: PMID 31831767 · NCT04218071 · Primary Myelofibrosis
  11. Glycogen Synthase Kinase-3 Inhibition Sensitizes Pancreatic Cancer Cells to Chemotherapy by Abrogating the TopBP1/ATR-Mediated DNA Damage Response.
    Ding L, Madamsetty VS, Kiers S, et al. · Clin Cancer Res · 2020 · Trial result
    PubMed: PMID 31533931 · NCT04218071 · Primary Myelofibrosis
  12. Clinically relevant GSK‑3β inhibitor 9‑ING‑41 is active as a single agent and in combination with other antitumor therapies in human renal cancer.
    Anraku T, Kuroki H, Kazama A, et al. · Int J Mol Med · 2020 · Trial result
    PubMed: PMID 31894292 · NCT04218071 · Primary Myelofibrosis
  13. Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease.
    Zeiser R, von Bubnoff N, Butler J, et al. · N Engl J Med · 2020 · Derived
    PubMed: PMID 32320566 · NCT02913261 (REACH2) · Graft vs Host Disease
  14. Persistent janus kinase-signaling in chronic lymphocytic leukemia patients on ibrutinib: Results of a phase I trial.
    Spaner DE, McCaw L, Wang G, et al. · Cancer Med · 2020 · Derived
    PubMed: PMID 30843659 · NCT02912754 · Leukemia, Lymphocytic, Chronic, B-Cell
  15. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial.
    Rosmarin D, Pandya AG, Lebwohl M, et al. · Lancet · 2020 · Derived
    PubMed: PMID 32653055 · NCT03099304 · Vitiligo
  16. A phase Ib study of the combination of afatinib and ruxolitinib in EGFR mutant NSCLC with progression on EGFR-TKIs.
    Park JS, Hong MH, Chun YJ, et al. · Lung Cancer · 2020 · Derived
    PubMed: PMID 31319994 · NCT02145637 · Neoplasms
  17. The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation.
    La Rosée F, Bremer HC, Gehrke I, et al. · Leukemia · 2020 · Derived
    PubMed: PMID 32518419 · NCT04338958 (RuxCoFlam) · COVID-19
  18. Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma.
    Kim SJ, Yoon DH, Kang HJ, et al. · BMC Cancer · 2020 · Derived
    PubMed: PMID 31707975 · NCT01965119 (JAK2) · Recurrence
  19. Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream.
    Kim BS, Howell MD, Sun K, et al. · J Allergy Clin Immunol · 2020 · Derived
    PubMed: PMID 31629805 · NCT03011892 · Dermatitis, Atopic
  20. Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study.
    Kiladjian JJ, Zachee P, Hino M, et al. · Lancet Haematol · 2020 · Derived
    PubMed: PMID 31982039 · NCT01243944 · Polycythemia Vera
  21. Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial.
    Jagasia M, Perales MA, Schroeder MA, et al. · Blood · 2020 · Derived
    PubMed: PMID 32160294 · NCT02953678 · Graft vs Host Disease
  22. A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis.
    Couban S, Benevolo G, Donnellan W, et al. · J Hematol Oncol · 2020 · Derived
    PubMed: PMID 30249277 · NCT02593760 · Primary Myelofibrosis
  23. A pneumonia outbreak associated with a new coronavirus of probable bat origin.
    Zhou P, Yang XL, Wang XG, et al. · Nature · 2020 · Background
    PubMed: PMID 32015507 · NCT04374149 · COVID-19
  24. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.
    Zhou F, Yu T, Du R, et al. · Lancet · 2020 · Background
    PubMed: PMID 32171076 · NCT04359290 (RuXoCoil) · COVID-19
  25. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study.
    Yang X, Yu Y, Xu J, et al. · Lancet Respir Med · 2020 · Background
    PubMed: PMID 32105632 · NCT04359290 (RuXoCoil) · COVID-19
  26. Plasma Exchange Can Be an Alternative Therapeutic Modality for Severe Cytokine Release Syndrome after Chimeric Antigen Receptor-T Cell Infusion: A Case Report.
    Xiao X, He X, Li Q, et al. · Clin Cancer Res · 2020 · Background
    PubMed: PMID 30322878 · NCT04374149 · COVID-19
  27. Clinical and CT features in pediatric patients with COVID-19 infection: Different points from adults.
    Xia W, Shao J, Guo Y, et al. · Pediatr Pulmonol · 2020 · Background
    PubMed: PMID 32134205 · NCT04359290 (RuXoCoil) · COVID-19
  28. Novel Coronavirus Infection in Hospitalized Infants Under 1 Year of Age in China.
    Wei M, Yuan J, Liu Y, et al. · JAMA · 2020 · Background
    PubMed: PMID 32058570 · NCT04359290 (RuXoCoil) · COVID-19
  29. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation.
    Penack O, Marchetti M, Ruutu T, et al. · Lancet Haematol · 2020 · Background
    PubMed: PMID 32004485 · NCT06756061 (FRONTJAK-001) · Graft vs Host Disease
  30. The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease.
    McGonagle D, Sharif K, O'Regan A, et al. · Autoimmun Rev · 2020 · Background
    PubMed: PMID 32251717 · NCT04414098 · COVID-19
  31. Update: Public Health Response to the Coronavirus Disease 2019 Outbreak - United States, February 24, 2020.
    Jernigan DB, CDC COVID-19 Response Team · MMWR Morb Mortal Wkly Rep · 2020 · Background
    PubMed: PMID 32106216 · NCT04374149 · COVID-19
  32. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.
    Huang C, Wang Y, Li X, et al. · Lancet · 2020 · Background
    PubMed: PMID 31986264 · NCT04359290 (RuXoCoil) · COVID-19
  33. Janus kinases to jakinibs: from basic insights to clinical practice.
    Gadina M, Le MT, Schwartz DM, et al. · Rheumatology (Oxford) · 2020 · Background
    PubMed: PMID 30806710 · NCT04414098 · COVID-19
  34. HDAC3 functions as a positive regulator in Notch signal transduction.
    Ferrante F, Giaimo BD, Bartkuhn M, et al. · Nucleic Acids Res · 2020 · Background
    PubMed: PMID 32107550 · NCT05088226
  35. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China].
    Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention · Zhonghua Liu Xing Bing Xue Za Zhi · 2020 · Background
    PubMed: PMID 32064853 · NCT04359290 (RuXoCoil) · COVID-19
  36. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies.
    Conti P, Ronconi G, Caraffa A, et al. · J Biol Regul Homeost Agents · 2020 · Background
    PubMed: PMID 32171193 · NCT04374149 · COVID-19
  37. Retrospective single center analysis of outcome, risk factors and therapy in steroid refractory graft-versus-host disease after allogeneic hematopoietic cell transplantation.
    Axt L, Naumann A, Toennies J, et al. · Bone Marrow Transplant · 2020 · Background
    PubMed: PMID 31089279 · NCT06756061 (FRONTJAK-001) · Graft vs Host Disease

2019 (27 papers)

  1. 9-ING-41, a small-molecule glycogen synthase kinase-3 inhibitor, is active in neuroblastoma.
    Ugolkov AV, Bondarenko GI, Dubrovskyi O, et al. · Anticancer Drugs · 2019 · Trial result
    PubMed: PMID 29846250 · NCT04218071 · Primary Myelofibrosis
  2. A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma.
    Van Den Neste E, André M, Gastinne T, et al. · Haematologica · 2019 · Derived
    PubMed: PMID 29351986 · NCT01877005 (HIJAK) · Hodgkin Disease
  3. Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study.
    Talpaz M, Erickson-Viitanen S, Hou K, et al. · J Hematol Oncol · 2019 · Derived
    PubMed: PMID 30086777 · NCT01445769 · Primary Myelofibrosis
  4. A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease.
    Sweet K, Hazlehurst L, Sahakian E, et al. · Leuk Res · 2019 · Derived
    PubMed: PMID 30340199 · NCT01702064 · Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  5. Ibrutinib reprograms the glucocorticoid receptor in chronic lymphocytic leukemia cells.
    Shi Y, Wang G, Muhowski EM, et al. · Leukemia · 2019 · Derived
    PubMed: PMID 30696950 · NCT02912754 · Leukemia, Lymphocytic, Chronic, B-Cell
  6. A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis.
    Masarova L, Verstovsek S, Hidalgo-Lopez JE, et al. · Blood · 2019 · Derived
    PubMed: PMID 30185431 · NCT01787487 · Primary Myelofibrosis
  7. Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis.
    Kvasnicka HM, Thiele J, Bueso-Ramos CE, et al. · J Hematol Oncol · 2019 · Derived
    PubMed: PMID 29544547 · NCT00509899 · Primary Myelofibrosis
  8. Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH  trials.
    Jagasia M, Zeiser R, Arbushites M, et al. · Immunotherapy · 2019 · Derived
    PubMed: PMID 29316837 · NCT03112603 · Graft vs Host Disease
  9. Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies.
    Hurwitz H, Van Cutsem E, Bendell J, et al. · Invest New Drugs · 2019 · Derived
    PubMed: PMID 29508247 · NCT02117479 · Pancreatic Neoplasms
  10. Ruxolitinib Therapy Followed by Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis: Myeloproliferative Disorders Research Consortium 114 Study.
    Gupta V, Kosiorek HE, Mead A, et al. · Biol Blood Marrow Transplant · 2019 · Derived
    PubMed: PMID 30205231 · NCT01790295 · Primary Myelofibrosis
  11. Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial.
    Ahmed A, Merrill SA, Alsawah F, et al. · Lancet Haematol · 2019 · Derived
    PubMed: PMID 31537486 · NCT02400463 · Lymphohistiocytosis, Hemophagocytic
  12. Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation.
    Abaza Y, Hidalgo-Lopez JE, Verstovsek S, et al. · Leuk Res · 2019 · Derived
    PubMed: PMID 30245189 · NCT01895842 · Leukemia
  13. Factors Associated With Clinical Remission of Skin Disease in Dermatomyositis.
    Wolstencroft PW, Chung L, Li S, et al. · JAMA Dermatol · 2019 · Background
    PubMed: PMID 29114741 · NCT06857240 · Dermatomyositis
  14. Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628).
    von Bubnoff N, Ihorst G, Grishina O, et al. · BMC Cancer · 2019 · Background
    PubMed: PMID 30453910 · NCT07340723 (GVHD)
  15. Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management.
    Tefferi A · Am J Hematol · 2019 · Background
    PubMed: PMID 30039550 · NCT05762874 · Primary Myelofibrosis
  16. MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis.
    Tefferi A, Guglielmelli P, Lasho TL, et al. · J Clin Oncol · 2019 · Background
    PubMed: PMID 29708808 · NCT05762874 · Primary Myelofibrosis
  17. Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy.
    Spiegel JY, McNamara C, Kennedy JA, et al. · Blood Adv · 2019 · Background
    PubMed: PMID 29296819 · NCT03959371 · Primary Myelofibrosis
  18. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
    Sandmaier BM, Kornblit B, Storer BE, et al. · Lancet Haematol · 2019 · Background
    PubMed: PMID 31248843 · NCT04397367
  19. Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel.
    Porter D, Frey N, Wood PA, et al. · J Hematol Oncol · 2019 · Background
    PubMed: PMID 29499750 · NCT04374149 · COVID-19
  20. Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study⁎.
    Palandri F, Palumbo GA, Iurlo A, et al. · Semin Hematol · 2019 · Background
    PubMed: PMID 30502854 · NCT05762874 · Primary Myelofibrosis
  21. MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD.
    Major-Monfried H, Renteria AS, Pawarode A, et al. · Blood · 2019 · Background
    PubMed: PMID 29545329 · NCT04061876
  22. JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis.
    Ladislau L, Suárez-Calvet X, Toquet S, et al. · Brain · 2019 · Background
    PubMed: PMID 29741608 · NCT06857240 · Dermatomyositis
  23. The JAK1/JAK2- inhibitor ruxolitinib inhibits mast cell degranulation and cytokine release.
    Hermans MAW, Schrijver B, van Holten-Neelen CCPA, et al. · Clin Exp Allergy · 2019 · Background
    PubMed: PMID 29939445 · NCT04359290 (RuXoCoil) · COVID-19
  24. MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis.
    Guglielmelli P, Lasho TL, Rotunno G, et al. · J Clin Oncol · 2019 · Background
    PubMed: PMID 29226763 · NCT03959371 · Primary Myelofibrosis
  25. Recommendations for the Use of Etoposide-Based Therapy and Bone Marrow Transplantation for the Treatment of HLH: Consensus Statements by the HLH Steering Committee of the Histiocyte Society.
    Ehl S, Astigarraga I, von Bahr Greenwood T, et al. · J Allergy Clin Immunol Pract · 2019 · Background
    PubMed: PMID 30201097 · NCT05491304 · Lymphohistiocytosis, Hemophagocytic
  26. Clinical efficacy of ruxolitinib and chemotherapy in a child with Philadelphia chromosome-like acute lymphoblastic leukemia with GOLGA5-JAK2 fusion and induction failure.
    Ding YY, Stern JW, Jubelirer TF, et al. · Haematologica · 2019 · Background
    PubMed: PMID 29773603 · NCT04582604
  27. Novel Inhaled Pan-JAK Inhibitor, LAS194046, Reduces Allergen-Induced Airway Inflammation, Late Asthmatic Response, and pSTAT Activation in Brown Norway Rats.
    Calbet M, Ramis I, Calama E, et al. · J Pharmacol Exp Ther · 2019 · Background
    PubMed: PMID 31085698 · NCT04359290 (RuXoCoil) · COVID-19

2018 (19 papers)

  1. Role of the inflammasome-related cytokines Il-1 and Il-18 during infection with murine coronavirus.
    Zalinger ZB, Elliott R, Weiss SR, et al. · J Neurovirol · 2018 · Trial result
    PubMed: PMID 28895072 · NCT04366232 (JAKINCOV) · COVID-19
  2. Activity of the Janus kinase inhibitor ruxolitinib in chronic lymphocytic leukemia: results of a phase II trial.
    Spaner DE, Wang G, McCaw L, et al. · Haematologica · 2018 · Trial result
    PubMed: PMID 26819050 · NCT02912754 · Leukemia, Lymphocytic, Chronic, B-Cell
  3. Janus and PI3-kinases mediate glucocorticoid resistance in activated chronic leukemia cells.
    Oppermann S, Lam AJ, Tung S, et al. · Oncotarget · 2018 · Trial result
    PubMed: PMID 27579615 · NCT02912754 · Leukemia, Lymphocytic, Chronic, B-Cell
  4. Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses.
    Verstovsek S, Gotlib J, Mesa RA, et al. · J Hematol Oncol · 2018 · Derived
    PubMed: PMID 28962635 · NCT00952289 · Primary Myelofibrosis
  5. Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I.
    Miller CB, Komrokji RS, Mesa RA, et al. · Clin Lymphoma Myeloma Leuk · 2018 · Derived
    PubMed: PMID 28606598 · NCT00952289 · Primary Myelofibrosis
  6. Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata.
    Mackay-Wiggan J, Jabbari A, Nguyen N, et al. · JCI Insight · 2018 · Derived
    PubMed: PMID 27699253 · NCT01950780 · Alopecia Areata
  7. Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies.
    Kiladjian JJ, Guglielmelli P, Griesshammer M, et al. · Ann Hematol · 2018 · Derived
    PubMed: PMID 29396713 · NCT01243944 · Polycythemia Vera
  8. [Efficacy and safety of JAK inhibitor ruxolitinib in Chinese patients with myelofibrosis: results of a 1-year follow-up of A2202].
    Jin J, Du X, Zhou DB, et al. · Zhonghua Xue Ye Xue Za Zhi · 2018 · Derived
    PubMed: PMID 27801315 · NCT01392443 · Primary Myelofibrosis
  9. A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms.
    Assi R, Kantarjian HM, Garcia-Manero G, et al. · Am J Hematol · 2018 · Derived
    PubMed: PMID 29134664 · NCT01787487 · Primary Myelofibrosis
  10. Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets.
    Zeiser R, Blazar BR · N Engl J Med · 2018 · Background
    PubMed: PMID 29281578 · NCT06756061 (FRONTJAK-001) · Graft vs Host Disease
  11. Ruxolitinib as first-line treatment in secondary hemophagocytic lymphohistiocytosis: A single patient experience.
    Slostad J, Hoversten P, Haddox CL, et al. · Am J Hematol · 2018 · Background
    PubMed: PMID 29134683 · NCT04414098 · COVID-19
  12. Driver mutations' effect in secondary myelofibrosis: an international multicenter study based on 781 patients.
    Passamonti F, Mora B, Giorgino T, et al. · Leukemia · 2018 · Background
    PubMed: PMID 27885272 · NCT03959371 · Primary Myelofibrosis
  13. Tofacitinib Citrate for Refractory Cutaneous Dermatomyositis: An Alternative Treatment.
    Kurtzman DJ, Wright NA, Lin J, et al. · JAMA Dermatol · 2018 · Background
    PubMed: PMID 27120749 · NCT06857240 · Dermatomyositis
  14. Treatment of Hypereosinophilic Syndrome with Cutaneous Involvement with the JAK Inhibitors Tofacitinib and Ruxolitinib.
    King B, Lee AI, Choi J, et al. · J Invest Dermatol · 2018 · Background
    PubMed: PMID 27887955 · NCT00044304 · Hypereosinophilic Syndrome
  15. Viral and bacterial co-infection in severe pneumonia triggers innate immune responses and specifically enhances IP-10: a translational study.
    Hoffmann J, Machado D, Terrier O, et al. · Sci Rep · 2018 · Background
    PubMed: PMID 27922126 · NCT04359290 (RuXoCoil) · COVID-19
  16. Efficacy and Safety of Unmanipulated Haploidentical Related Donor Allogeneic Peripheral Blood Stem Cell Transplantation in Patients with Relapsed/Refractory Acute Myeloid Leukemia.
    Dou LP, Li HH, Wang L, et al. · Chin Med J (Engl) · 2018 · Background
    PubMed: PMID 29578122 · NCT04397367
  17. Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation.
    Betts BC, Bastian D, Iamsawat S, et al. · Proc Natl Acad Sci U S A · 2018 · Background
    PubMed: PMID 29382747 · NCT07509749 (GVHD) · Graft vs Host Disease
  18. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study.
    Bergsten E, Horne A, Aricó M, et al. · Blood · 2018 · Background
    PubMed: PMID 28935695 · NCT05491304 · Lymphohistiocytosis, Hemophagocytic
  19. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion.
    Barbui T, Thiele J, Gisslinger H, et al. · Blood Cancer J · 2018 · Background
    PubMed: PMID 29426921 · NCT05762874 · Primary Myelofibrosis

2017 (27 papers)

  1. GSK-3 inhibition overcomes chemoresistance in human breast cancer.
    Ugolkov A, Gaisina I, Zhang JS, et al. · Cancer Lett · 2017 · Trial result
    PubMed: PMID 27424289 · NCT04218071 · Primary Myelofibrosis
  2. The EBMT-ELN working group recommendations on the prophylaxis and treatment of GvHD: a change-control analysis.
    Ruutu T, Gratwohl A, Niederwieser D, et al. · Bone Marrow Transplant · 2017 · Trial result
    PubMed: PMID 27892949 · NCT04397367
  3. The EQ-5D-5L valuation study in Korea.
    Kim SH, Ahn J, Ock M, et al. · Qual Life Res · 2017 · Trial result
    PubMed: PMID 26961008 · NCT06756061 (FRONTJAK-001) · Graft vs Host Disease
  4. Inhibition of Glycogen Synthase Kinase 3β Blocks Mesomesenchymal Transition and Attenuates Streptococcus pneumonia-Mediated Pleural Injury in Mice.
    Boren J, Shryock G, Fergis A, et al. · Am J Pathol · 2017 · Trial result
    PubMed: PMID 29073967 · NCT04218071 · Primary Myelofibrosis
  5. Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial.
    Verstovsek S, Vannucchi AM, Griesshammer M, et al. · Haematologica · 2017 · Derived
    PubMed: PMID 27102499 · NCT01243944 · Polycythemia Vera
  6. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.
    Verstovsek S, Mesa RA, Gotlib J, et al. · J Hematol Oncol · 2017 · Derived
    PubMed: PMID 28228106 · NCT00952289 · Primary Myelofibrosis
  7. Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy.
    Verstovsek S, Harrison CN, Kiladjian JJ, et al. · Leuk Res · 2017 · Derived
    PubMed: PMID 28193568 · NCT01243944 · Polycythemia Vera
  8. Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study.
    Passamonti F, Griesshammer M, Palandri F, et al. · Lancet Oncol · 2017 · Derived
    PubMed: PMID 27916398 · NCT02038036 (RESPONSE-2) · Myeloproliferative Disorders
  9. Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial.
    Jain P, Keating M, Renner S, et al. · Lancet Haematol · 2017 · Derived
    PubMed: PMID 28089238 · NCT02131584 · Leukemia, Lymphocytic, Chronic, B-Cell
  10. Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata.
    Bayart CB, DeNiro KL, Brichta L, et al. · J Am Acad Dermatol · 2017 · Derived
    PubMed: PMID 28619556 · NCT02553330 · Alopecia Areata
  11. Protective effect of suppressing STAT3 activity in LPS-induced acute lung injury.
    Zhao J, Yu H, Liu Y, et al. · Am J Physiol Lung Cell Mol Physiol · 2017 · Background
    PubMed: PMID 27638904 · NCT04359290 (RuXoCoil) · COVID-19
  12. Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China.
    Shi Y, Jia B, Xu W, et al. · J Hematol Oncol · 2017 · Background
    PubMed: PMID 28298231 · NCT05075681
  13. Mutations in MPNs: prognostic implications, window to biology, and impact on treatment decisions.
    Shammo JM, Stein BL · Hematology Am Soc Hematol Educ Program · 2017 · Background
    PubMed: PMID 27913528 · NCT05762874 · Primary Myelofibrosis
  14. The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL.
    Savino AM, Sarno J, Trentin L, et al. · Leukemia · 2017 · Background
    PubMed: PMID 28331226 · NCT05088226
  15. Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group.
    Rotunno G, Pacilli A, Artusi V, et al. · Am J Hematol · 2017 · Background
    PubMed: PMID 27037840 · NCT03959371 · Primary Myelofibrosis
  16. Update from the latest WHO classification of MPNs: a user's manual.
    Passamonti F, Maffioli M · Hematology Am Soc Hematol Educ Program · 2017 · Background
    PubMed: PMID 27913526 · NCT03959371 · Primary Myelofibrosis
  17. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis.
    Passamonti F, Giorgino T, Mora B, et al. · Leukemia · 2017 · Background
    PubMed: PMID 28561069 · NCT03959371 · Primary Myelofibrosis
  18. Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation.
    Newberry KJ, Patel K, Masarova L, et al. · Blood · 2017 · Background
    PubMed: PMID 28674026 · NCT03959371 · Primary Myelofibrosis
  19. Rituximab-based first-line treatment of cGVHD after allogeneic SCT: results of a phase 2 study.
    Malard F, Labopin M, Yakoub-Agha I, et al. · Blood · 2017 · Background
    PubMed: PMID 28864814 · NCT06756061 (FRONTJAK-001) · Graft vs Host Disease
  20. A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study.
    Levine JE, Braun TM, Harris AC, et al. · Lancet Haematol · 2017 · Background
    PubMed: PMID 26687425 · NCT04061876
  21. Clinical features predict responsiveness to imatinib in platelet-derived growth factor receptor-alpha-negative hypereosinophilic syndrome.
    Khoury P, Desmond R, Pabon A, et al. · Allergy · 2017 · Background
    PubMed: PMID 26797802 · NCT00044304 · Hypereosinophilic Syndrome
  22. JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML.
    Karjalainen R, Pemovska T, Popa M, et al. · Blood · 2017 · Background
    PubMed: PMID 28619982 · NCT04582604
  23. Childhood Arthritis and Rheumatology Research Alliance Consensus Clinical Treatment Plans for Juvenile Dermatomyositis with Persistent Skin Rash.
    Huber AM, Kim S, Reed AM, et al. · J Rheumatol · 2017 · Background
    PubMed: PMID 27803135 · NCT06857240 · Dermatomyositis
  24. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis.
    Harrison CN, Vannucchi AM, Kiladjian JJ, et al. · Leukemia · 2017 · Background
    PubMed: PMID 27211272 · NCT03959371 · Primary Myelofibrosis
  25. JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias.
    Delgado-Martin C, Meyer LK, Huang BJ, et al. · Leukemia · 2017 · Background
    PubMed: PMID 28484265 · NCT05088226
  26. JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects.
    Banerjee S, Biehl A, Gadina M, et al. · Drugs · 2017 · Background
    PubMed: PMID 28255960 · NCT04414098 · COVID-19
  27. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.
    Arber DA, Orazi A, Hasserjian R, et al. · Blood · 2017 · Background
    PubMed: PMID 27069254 · NCT03959371 · Primary Myelofibrosis

2016 (11 papers)

  1. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey.
    Zeiser R, Burchert A, Lengerke C, et al. · Leukemia · 2016 · Trial result
    PubMed: PMID 26228813 · NCT04397367
  2. Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report.
    Lee SJ, Wolff D, Kitko C, et al. · Biol Blood Marrow Transplant · 2016 · Trial result
    PubMed: PMID 25796139 · NCT06756061 (FRONTJAK-001) · Graft vs Host Disease
  3. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis.
    Vannucchi AM, Kantarjian HM, Kiladjian JJ, et al. · Haematologica · 2016 · Derived
    PubMed: PMID 26069290 · NCT00934544 · Primary Myelofibrosis
  4. Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed.
    Hurwitz HI, Uppal N, Wagner SA, et al. · J Clin Oncol · 2016 · Derived
    PubMed: PMID 26351344 · NCT01423604 (RECAP) · Pancreatic Neoplasms
  5. Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis.
    Daver N, Cortes J, Newberry K, et al. · Haematologica · 2016 · Derived
    PubMed: PMID 26088933 · NCT01375140 · Primary Myelofibrosis
  6. Improvement in the cutaneous disease activity of patients with dermatomyositis is associated with a better quality of life.
    Robinson ES, Feng R, Okawa J, et al. · Br J Dermatol · 2016 · Background
    PubMed: PMID 24909747 · NCT06857240 · Dermatomyositis
  7. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group Report.
    Martin PJ, Lee SJ, Przepiorka D, et al. · Biol Blood Marrow Transplant · 2016 · Background
    PubMed: PMID 25985921 · NCT06756061 (FRONTJAK-001) · Graft vs Host Disease
  8. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group.
    Kröger NM, Deeg JH, Olavarria E, et al. · Leukemia · 2016 · Background
    PubMed: PMID 26293647 · NCT03959371 · Primary Myelofibrosis
  9. An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors.
    Jonas O, Landry HM, Fuller JE, et al. · Sci Transl Med · 2016 · Background
    PubMed: PMID 25904741 · NCT07352566 · Dermatitis, Atopic
  10. The proinflammatory role of HECTD2 in innate immunity and experimental lung injury.
    Coon TA, McKelvey AC, Lear T, et al. · Sci Transl Med · 2016 · Background
    PubMed: PMID 26157031 · NCT04359290 (RuXoCoil) · COVID-19
  11. Topical corticosteroid-induced skin atrophy: a comprehensive review.
    Barnes L, Kaya G, Rollason V, et al. · Drug Saf · 2016 · Background
    PubMed: PMID 25862024 · NCT06857240 · Dermatomyositis

2015 (21 papers)

  1. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.
    Verstovsek S, Mesa RA, Gotlib J, et al. · Haematologica · 2015 · Trial result
    PubMed: PMID 25616577 · NCT00952289 · Primary Myelofibrosis
  2. Inhibition of GSK-3 induces differentiation and impaired glucose metabolism in renal cancer.
    Pal K, Cao Y, Gaisina IN, et al. · Mol Cancer Ther · 2015 · Trial result
    PubMed: PMID 24327518 · NCT04218071 · Primary Myelofibrosis
  3. Ruxolitinib versus standard therapy for the treatment of polycythemia vera.
    Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. · N Engl J Med · 2015 · Derived
    PubMed: PMID 25629741 · NCT01243944 · Polycythemia Vera
  4. JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib.
    Pieri L, Pancrazzi A, Pacilli A, et al. · Blood · 2015 · Derived
    PubMed: PMID 25999444 · NCT00726232 · Myeloproliferative Disorders
  5. A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia.
    Pemmaraju N, Kantarjian H, Kadia T, et al. · Clin Lymphoma Myeloma Leuk · 2015 · Derived
    PubMed: PMID 25441108 · NCT01251965 · Leukemia, Myeloid, Acute
  6. Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I.
    Mesa RA, Verstovsek S, Gupta V, et al. · Clin Lymphoma Myeloma Leuk · 2015 · Derived
    PubMed: PMID 25682576 · NCT00952289 · Primary Myelofibrosis
  7. The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis.
    McMullin MF, Harrison CN, Niederwieser D, et al. · Exp Hematol Oncol · 2015 · Derived
    PubMed: PMID 26380150 · NCT00934544 · Primary Myelofibrosis
  8. The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis.
    Deininger M, Radich J, Burn TC, et al. · Blood · 2015 · Derived
    PubMed: PMID 26228487 · NCT00952289 · Primary Myelofibrosis
  9. An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults.
    Savona MR, Malcovati L, Komrokji R, et al. · Blood · 2015 · Background
    PubMed: PMID 25624319 · NCT02092324 · Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
  10. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.
    Rumi E, Pietra D, Pascutto C, et al. · Blood · 2015 · Background
    PubMed: PMID 24986690 · NCT03959371 · Primary Myelofibrosis
  11. The efficacy and safety of plasma exchange in patients with sepsis and septic shock: a systematic review and meta-analysis.
    Rimmer E, Houston BL, Kumar A, et al. · Crit Care · 2015 · Background
    PubMed: PMID 25527094 · NCT04374149 · COVID-19
  12. Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms.
    Rampal R, Ahn J, Abdel-Wahab O, et al. · Proc Natl Acad Sci U S A · 2015 · Background
    PubMed: PMID 25516983 · NCT04582604
  13. Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia.
    Maude SL, Dolai S, Delgado-Martin C, et al. · Blood · 2015 · Background
    PubMed: PMID 25645356 · NCT05088226
  14. How I treat hypereosinophilic syndromes.
    Klion AD · Blood · 2015 · Background
    PubMed: PMID 25964669 · NCT00044304 · Hypereosinophilic Syndrome
  15. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report.
    Jagasia MH, Greinix HT, Arora M, et al. · Biol Blood Marrow Transplant · 2015 · Background
    PubMed: PMID 25529383 · NCT06756061 (FRONTJAK-001) · Graft vs Host Disease
  16. Remission of recalcitrant dermatomyositis treated with ruxolitinib.
    Hornung T, Janzen V, Heidgen FJ, et al. · N Engl J Med · 2015 · Background
    PubMed: PMID 25539124 · NCT06857240 · Dermatomyositis
  17. How we treat chronic graft-versus-host disease.
    Flowers ME, Martin PJ · Blood · 2015 · Background
    PubMed: PMID 25398933 · NCT06756061 (FRONTJAK-001) · Graft vs Host Disease
  18. Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect.
    Choi J, Cooper ML, Alahmari B, et al. · PLoS One · 2015 · Background
    PubMed: PMID 25289677 · NCT03395340 · Graft vs Host Disease
  19. How I treat myelofibrosis.
    Cervantes F · Blood · 2015 · Background
    PubMed: PMID 25232060 · NCT05762874 · Primary Myelofibrosis
  20. Amyopathic dermatomyositis: definitions, diagnosis, and management.
    Bailey EE, Fiorentino DF · Curr Rheumatol Rep · 2015 · Background
    PubMed: PMID 25366932 · NCT06857240 · Dermatomyositis
  21. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research.
    Arai S, Arora M, Wang T, et al. · Biol Blood Marrow Transplant · 2015 · Background
    PubMed: PMID 25445023 · NCT06756061 (FRONTJAK-001) · Graft vs Host Disease

2014 (14 papers)

  1. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I.
    Verstovsek S, Mesa RA, Gotlib J, et al. · Haematologica · 2014 · Trial result
    PubMed: PMID 24038026 · NCT00952289 · Primary Myelofibrosis
  2. Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib.
    Wilkins BS, Radia D, Woodley C, et al. · Haematologica · 2014 · Derived
    PubMed: PMID 24056820 · NCT00934544 · Primary Myelofibrosis
  3. Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts.
    Talpaz M, Paquette R, Afrin L, et al. · J Hematol Oncol · 2014 · Derived
    PubMed: PMID 24283202 · NCT01348490 · Myeloproliferative Disorders
  4. Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies.
    Mesa RA, Kiladjian JJ, Verstovsek S, et al. · Haematologica · 2014 · Derived
    PubMed: PMID 23911705 · NCT00934544 · Primary Myelofibrosis
  5. Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia.
    Dao KH, Solti MB, Maxson JE, et al. · Leuk Res Rep · 2014 · Derived
    PubMed: PMID 25180155 · NCT02092324 · Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
  6. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.
    Cervantes F, Vannucchi AM, Kiladjian JJ, et al. · Blood · 2014 · Derived
    PubMed: PMID 24174625 · NCT00934544 · Primary Myelofibrosis
  7. How common are myeloproliferative neoplasms? A systematic review and meta-analysis.
    Titmarsh GJ, Duncombe AS, McMullin MF, et al. · Am J Hematol · 2014 · Background
    PubMed: PMID 24971434 · NCT05762874 · Primary Myelofibrosis
  8. Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease.
    Spoerl S, Mathew NR, Bscheider M, et al. · Blood · 2014 · Background
    PubMed: PMID 24711661 · NCT06756061 (FRONTJAK-001) · Graft vs Host Disease
  9. Disease activity and prognostic factors in juvenile dermatomyositis: a long-term follow-up study applying the Paediatric Rheumatology International Trials Organization criteria for inactive disease and the myositis disease activity assessment tool.
    Sanner H, Sjaastad I, Flatø B, et al. · Rheumatology (Oxford) · 2014 · Background
    PubMed: PMID 24692575 · NCT06857240 · Dermatomyositis
  10. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union.
    Moulard O, Mehta J, Fryzek J, et al. · Eur J Haematol · 2014 · Background
    PubMed: PMID 24372927 · NCT05762874 · Primary Myelofibrosis
  11. Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?
    Heine A, Brossart P, Wolf D, et al. · Blood · 2014 · Background
    PubMed: PMID 24288410 · NCT03959371 · Primary Myelofibrosis
  12. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study.
    Guglielmelli P, Biamonte F, Rotunno G, et al. · Blood · 2014 · Background
    PubMed: PMID 24458439 · NCT03959371 · Primary Myelofibrosis
  13. Chemomodulation of sequential high-dose cytarabine by fludarabine in relapsed or refractory acute myeloid leukemia: a randomized trial of the AMLCG.
    Fiegl M, Unterhalt M, Kern W, et al. · Leukemia · 2014 · Background
    PubMed: PMID 24150216 · NCT07101588
  14. Ruxolitinib.
    Becker H, Engelhardt M, von Bubnoff N, et al. · Recent Results Cancer Res · 2014 · Background
    PubMed: PMID 24756798 · NCT06991101 · Glioblastoma

2013 (4 papers)

  1. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial.
    Mesa RA, Gotlib J, Gupta V, et al. · J Clin Oncol · 2013 · Derived
    PubMed: PMID 23423753 · NCT00952289 · Primary Myelofibrosis
  2. Mutations and prognosis in primary myelofibrosis.
    Vannucchi AM, Lasho TL, Guglielmelli P, et al. · Leukemia · 2013 · Background
    PubMed: PMID 23619563 · NCT03959371 · Primary Myelofibrosis
  3. Acute myeloid leukemia following a myeloproliferative neoplasm: clinical characteristics, genetic features and effects of therapy.
    Heaney ML, Soriano G · Curr Hematol Malig Rep · 2013 · Background
    PubMed: PMID 23572311 · NCT03558607
  4. Graft-versus-tumor effect according to type of graft-versus-host disease defined by National Institutes of Health consensus criteria and associated outcomes.
    Cho BS, Lee SE, Song HH, et al. · Biol Blood Marrow Transplant · 2013 · Background
    PubMed: PMID 22261380 · NCT06756061 (FRONTJAK-001) · Graft vs Host Disease

2012 (13 papers)

  1. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
    Verstovsek S, Mesa RA, Gotlib J, et al. · N Engl J Med · 2012 · Trial result
    PubMed: PMID 22375971 · NCT00952289 · Primary Myelofibrosis
  2. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.
    Verstovsek S, Kantarjian HM, Estrov Z, et al. · Blood · 2012 · Trial result
    PubMed: PMID 22718840 · NCT00509899 · Primary Myelofibrosis
  3. Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis.
    Punwani N, Scherle P, Flores R, et al. · J Am Acad Dermatol · 2012 · Derived
    PubMed: PMID 22281165 · NCT00820950 · Psoriasis
  4. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
    Harrison C, Kiladjian JJ, Al-Ali HK, et al. · N Engl J Med · 2012 · Derived
    PubMed: PMID 22375970 · NCT00934544 · Primary Myelofibrosis
  5. [Nationwide survey of adult T-cell leukemia/lymphoma (ATL) in Japan].
    Yamada Y, Atogami S, Hasegawa H, et al. · Rinsho Ketsueki · 2012 · Background
    PubMed: PMID 22185799 · NCT01712659 · Leukemia-Lymphoma, Adult T-Cell
  6. Diagnostic accuracy of a specific cytokine pattern in hemophagocytic lymphohistiocytosis in children.
    Xu XJ, Tang YM, Song H, et al. · J Pediatr · 2012 · Background
    PubMed: PMID 22226576 · NCT05491304 · Lymphohistiocytosis, Hemophagocytic
  7. Connectivity mapping identifies HDAC inhibitors for the treatment of t(4;11)-positive infant acute lymphoblastic leukemia.
    Stumpel DJ, Schneider P, Seslija L, et al. · Leukemia · 2012 · Background
    PubMed: PMID 22015773 · NCT05075681
  8. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI).
    Rider LG, Werth VP, Huber AM, et al. · Arthritis Care Res (Hoboken) · 2012 · Background
    PubMed: PMID 22588740 · NCT06857240 · Dermatomyositis
  9. Significantly worse survival of patients with NIH-defined chronic graft-versus-host disease and thrombocytopenia or progressive onset type: results of a prospective study.
    Kuzmina Z, Eder S, Böhm A, et al. · Leukemia · 2012 · Background
    PubMed: PMID 21926960 · NCT04061876
  10. Evaluation of reliability, validity, and responsiveness of the CDASI and the CAT-BM.
    Goreshi R, Okawa J, Rose M, et al. · J Invest Dermatol · 2012 · Background
    PubMed: PMID 22217740 · NCT06857240 · Dermatomyositis
  11. Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia.
    Eghtedar A, Verstovsek S, Estrov Z, et al. · Blood · 2012 · Background
    PubMed: PMID 22422826 · NCT03558607
  12. Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase.
    Cherington C, Slack JL, Leis J, et al. · Leuk Res · 2012 · Background
    PubMed: PMID 22578777 · NCT03558607
  13. Advances in graft-versus-host disease biology and therapy.
    Blazar BR, Murphy WJ, Abedi M, et al. · Nat Rev Immunol · 2012 · Background
    PubMed: PMID 22576252 · NCT06756061 (FRONTJAK-001) · Graft vs Host Disease

2011 (7 papers)

  1. Aberrant interferon-signaling is associated with aggressive chronic lymphocytic leukemia.
    Tomic J, Lichty B, Spaner DE, et al. · Blood · 2011 · Background
    PubMed: PMID 21205928 · NCT02015208 · Leukemia, Lymphocytic, Chronic, B-Cell
  2. Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium.
    Pidala J, Kurland B, Chai X, et al. · Blood · 2011 · Background
    PubMed: PMID 21355084 · NCT06756061 (FRONTJAK-001) · Graft vs Host Disease
  3. Use of therapeutic plasma exchange as a rescue therapy in 2009 pH1N1 influenza A--an associated respiratory failure and hemodynamic shock.
    Patel P, Nandwani V, Vanchiere J, et al. · Pediatr Crit Care Med · 2011 · Background
    PubMed: PMID 20453703 · NCT04374149 · COVID-19
  4. Human T-cell leukemia virus type 1 (HTLV-1) and leukemic transformation: viral infectivity, Tax, HBZ and therapy.
    Matsuoka M, Jeang KT · Oncogene · 2011 · Background
    PubMed: PMID 21119600 · NCT01712659 · Leukemia-Lymphoma, Adult T-Cell
  5. Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3.
    Guryanova OA, Wu Q, Cheng L, et al. · Cancer Cell · 2011 · Background
    PubMed: PMID 21481791 · NCT06991101 · Glioblastoma
  6. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.
    Gangat N, Caramazza D, Vaidya R, et al. · J Clin Oncol · 2011 · Background
    PubMed: PMID 21149668 · NCT03959371 · Primary Myelofibrosis
  7. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients.
    Caramazza D, Begna KH, Gangat N, et al. · Leukemia · 2011 · Background
    PubMed: PMID 20944670 · NCT03959371 · Primary Myelofibrosis

2010 (9 papers)

  1. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.
    Verstovsek S, Kantarjian H, Mesa RA, et al. · N Engl J Med · 2010 · Trial result
    PubMed: PMID 20843246 · NCT00509899 · Primary Myelofibrosis
  2. Modification of the cutaneous dermatomyositis disease area and severity index, an outcome instrument.
    Yassaee M, Fiorentino D, Okawa J, et al. · Br J Dermatol · 2010 · Background
    PubMed: PMID 19863510 · NCT06857240 · Dermatomyositis
  3. The graft-versus-leukemia effect is mainly restricted to NIH-defined chronic graft-versus-host disease after reduced intensity conditioning before allogeneic stem cell transplantation.
    Thepot S, Zhou J, Perrot A, et al. · Leukemia · 2010 · Background
    PubMed: PMID 20827288 · NCT04061876
  4. Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies.
    Rider LG, Koziol D, Giannini EH, et al. · Arthritis Care Res (Hoboken) · 2010 · Background
    PubMed: PMID 20391500 · NCT06857240 · Dermatomyositis
  5. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).
    Passamonti F, Cervantes F, Vannucchi AM, et al. · Blood · 2010 · Background
    PubMed: PMID 20008785 · NCT03959371 · Primary Myelofibrosis
  6. Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis.
    Mesa RA · IDrugs · 2010 · Background
    PubMed: PMID 20506062 · NCT05762874 · Primary Myelofibrosis
  7. Prognosis of secondary acute myeloid leukemia is affected by the type of the preceding hematologic disorders and the presence of trisomy 8.
    Koh Y, Kim I, Bae JY, et al. · Jpn J Clin Oncol · 2010 · Background
    PubMed: PMID 20587614 · NCT03558607
  8. Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm.
    Beer PA, Delhommeau F, LeCouédic JP, et al. · Blood · 2010 · Background
    PubMed: PMID 20008300 · NCT03558607
  9. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.
    Abdel-Wahab O, Manshouri T, Patel J, et al. · Cancer Res · 2010 · Background
    PubMed: PMID 20068184 · NCT03558607

2009 (6 papers)

  1. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting.
    Tsukasaki K, Hermine O, Bazarbachi A, et al. · J Clin Oncol · 2009 · Background
    PubMed: PMID 19064971 · NCT01712659 · Leukemia-Lymphoma, Adult T-Cell
  2. Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease.
    Martin PJ, Storer BE, Rowley SD, et al. · Blood · 2009 · Background
    PubMed: PMID 19270260 · NCT06756061 (FRONTJAK-001) · Graft vs Host Disease
  3. Graft-versus-host disease.
    Ferrara JL, Levine JE, Reddy P, et al. · Lancet · 2009 · Background
    PubMed: PMID 19282026 · NCT06756061 (FRONTJAK-001) · Graft vs Host Disease
  4. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.
    Cervantes F, Dupriez B, Pereira A, et al. · Blood · 2009 · Background
    PubMed: PMID 18988864 · NCT05762874 · Primary Myelofibrosis
  5. Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients.
    Camera A, Rinaldi CR, Palmieri S, et al. · Ann Hematol · 2009 · Background
    PubMed: PMID 18709502 · NCT07101588
  6. AML transformation in 56 patients with Ph- MPD in two well defined populations.
    Abdulkarim K, Girodon F, Johansson P, et al. · Eur J Haematol · 2009 · Background
    PubMed: PMID 19134023 · NCT03558607

2008 (8 papers)

  1. Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing.
    Klion AD, Robyn J, Maric I, et al. · Blood · 2008 · Derived
    PubMed: PMID 17709602 · NCT00044304 · Hypereosinophilic Syndrome
  2. The 'handprint' approximates to 1% of the total body surface area whereas the 'palm minus the fingers' does not.
    Thomas CL, Finlay AY · Br J Dermatol · 2008 · Background
    PubMed: PMID 17854369 · NCT06857240 · Dermatomyositis
  3. Early diagnostic and prognostic significance of a specific Th1/Th2 cytokine pattern in children with haemophagocytic syndrome.
    Tang Y, Xu X, Song H, et al. · Br J Haematol · 2008 · Background
    PubMed: PMID 18673367 · NCT05491304 · Lymphohistiocytosis, Hemophagocytic
  4. The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms.
    Tam CS, Nussenzveig RM, Popat U, et al. · Blood · 2008 · Background
    PubMed: PMID 18566326 · NCT03558607
  5. The role of aggressive corticosteroid therapy in patients with juvenile dermatomyositis: a propensity score analysis.
    Seshadri R, Feldman BM, Ilowite N, et al. · Arthritis Rheum · 2008 · Background
    PubMed: PMID 18576304 · NCT06857240 · Dermatomyositis
  6. Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis.
    Klein RQ, Bangert CA, Costner M, et al. · Br J Dermatol · 2008 · Background
    PubMed: PMID 18616782 · NCT06857240 · Dermatomyositis
  7. Development and validation of the Dermatomyositis Skin Severity Index.
    Carroll CL, Lang W, Snively B, et al. · Br J Dermatol · 2008 · Background
    PubMed: PMID 18067478 · NCT06857240 · Dermatomyositis
  8. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment.
    Barosi G, Mesa RA, Thiele J, et al. · Leukemia · 2008 · Background
    PubMed: PMID 17728787 · NCT03959371 · Primary Myelofibrosis

2007 (1 paper)

  1. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis.
    Henter JI, Horne A, Aricó M, et al. · Pediatr Blood Cancer · 2007 · Background
    PubMed: PMID 16937360 · NCT05491304 · Lymphohistiocytosis, Hemophagocytic

2006 (4 papers)

  1. European consensus on grading bone marrow fibrosis and assessment of cellularity.
    Thiele J, Kvasnicka HM, Facchetti F, et al. · Haematologica · 2006 · Background
    PubMed: PMID 16079113 · NCT03959371 · Primary Myelofibrosis
  2. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation.
    Schmid C, Schleuning M, Schwerdtfeger R, et al. · Blood · 2006 · Background
    PubMed: PMID 16551971 · NCT07101588
  3. Adverse effects of topical glucocorticosteroids.
    Hengge UR, Ruzicka T, Schwartz RA, et al. · J Am Acad Dermatol · 2006 · Background
    PubMed: PMID 16384751 · NCT06857240 · Dermatomyositis
  4. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis siné myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies.
    Gerami P, Schope JM, McDonald L, et al. · J Am Acad Dermatol · 2006 · Background
    PubMed: PMID 16546580 · NCT06857240 · Dermatomyositis

2005 (3 papers)

  1. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
    Stupp R, Mason WP, van den Bent MJ, et al. · N Engl J Med · 2005 · Background
    PubMed: PMID 15758009 · NCT06991101 · Glioblastoma
  2. Leukemic transformation of polycythemia vera: a single center study of 23 patients.
    Passamonti F, Rumi E, Arcaini L, et al. · Cancer · 2005 · Background
    PubMed: PMID 16047334 · NCT03558607
  3. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases.
    Mesa RA, Li CY, Ketterling RP, et al. · Blood · 2005 · Background
    PubMed: PMID 15388582 · NCT03558607

2004 (2 papers)

  1. Chronic graft-versus-host disease.
    Lee SJ, Vogelsang G, Flowers ME, et al. · Biol Blood Marrow Transplant · 2004 · Background
    PubMed: PMID 12720215 · NCT06756061 (FRONTJAK-001) · Graft vs Host Disease
  2. Topical tacrolimus in cutaneous lesions of dermatomyositis: lack of effect in side-by-side comparison in five patients.
    García-Doval I, Cruces M · Dermatology · 2004 · Background
    PubMed: PMID 15459546 · NCT06857240 · Dermatomyositis

2003 (1 paper)

  1. Plasmapheresis in severe sepsis and septic shock: a prospective, randomised, controlled trial.
    Busund R, Koukline V, Utrobin U, et al. · Intensive Care Med · 2003 · Background
    PubMed: PMID 12373468 · NCT04374149 · COVID-19

2002 (2 papers)

  1. Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone.
    Koc S, Leisenring W, Flowers ME, et al. · Blood · 2002 · Background
    PubMed: PMID 12070007 · NCT06756061 (FRONTJAK-001) · Graft vs Host Disease
  2. Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease.
    Arora M, Wagner JE, Davies SM, et al. · Biol Blood Marrow Transplant · 2002 · Background
    PubMed: PMID 11400948 · NCT06756061 (FRONTJAK-001) · Graft vs Host Disease

2001 (1 paper)

  1. Risk factors for chronic graft-versus-host disease after allogeneic stem cell transplantation in children.
    Kondo M, Kojima S, Horibe K, et al. · Bone Marrow Transplant · 2001 · Background
    PubMed: PMID 11360113 · NCT06756061 (FRONTJAK-001) · Graft vs Host Disease

2000 (1 paper)

  1. Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines.
    Barosi G · J Clin Oncol · 2000 · Background
    PubMed: PMID 10561375 · NCT05762874 · Primary Myelofibrosis

1998 (1 paper)

  1. Dermatomyositis: a dermatology-based case series.
    Dawkins MA, Jorizzo JL, Walker FO, et al. · J Am Acad Dermatol · 1998 · Background
    PubMed: PMID 9520020 · NCT06857240 · Dermatomyositis

1995 (1 paper)

  1. Vasoactive intestinal peptide gene expression in the rat pheochromocytoma cell line PC12.
    Tsukada T, Fukushima M, Takebe H, et al. · Mol Cell Endocrinol · 1995 · Background
    PubMed: PMID 7768335 · NCT07101588

1993 (1 paper)

  1. Amyopathic dermatomyositis: a review.
    Euwer RL, Sontheimer RD · J Invest Dermatol · 1993 · Background
    PubMed: PMID 8423381 · NCT06857240 · Dermatomyositis

1989 (1 paper)

  1. Optimal two-stage designs for phase II clinical trials.
    Simon R · Control Clin Trials · 1989 · Background
    PubMed: PMID 2702835 · NCT03558607

1978 (1 paper)

  1. Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis.
    Jacobson RJ, Salo A, Fialkow PJ, et al. · Blood · 1978 · Background
    PubMed: PMID 620081 · NCT05762874 · Primary Myelofibrosis

1975 (2 papers)

  1. Polymyositis and dermatomyositis (second of two parts).
    Bohan A, Peter JB · N Engl J Med · 1975 · Background
    PubMed: PMID 1089199 · NCT06857240 · Dermatomyositis
  2. Polymyositis and dermatomyositis (first of two parts).
    Bohan A, Peter JB · N Engl J Med · 1975 · Background
    PubMed: PMID 1090839 · NCT06857240 · Dermatomyositis

1974 (1 paper)

  1. The earliest history of famine and pestilence in Ethiopia and a note on the "Egyptian Deaths" of 17th and 18th century Ethiopia.
    Pankhurst R · Ethiop Med J · 1974 · Background
    PubMed: PMID 4602511 · NCT07101588

1973 (1 paper)

  1. Role of the liver in controlling the immunogenicity of commensal bacteria in the gut.
    Thomas HC, McSween RN, White RG, et al. · Lancet · 1973 · Background
    PubMed: PMID 4126078 · NCT07101588

1970 (1 paper)

  1. [Drug tolerance in microorganisms, with special reference to genetic study of its transmission].
    Watanabe T · Nihon Saikingaku Zasshi · 1970 · Background
    PubMed: PMID 4908810 · NCT07101588

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).